Appendix

For: An integrated epidemiologic and economic model to assess optimal COVID-19 pandemic policy (Joshua Szanyi, Tim Wilson, Samantha Howe, Jessie Zeng, Hassan Andrabi, Tony Blakely)

CONTENTS

1	Age	nt-based model2			
	1.1	Overview and input parameters	2		
	1.2	ABM calibration	.4		
2	Мос	delled scenarios	6		
	2.1	Policy options	6		
	2.1.2	1 Suppression policy	6		
	2.1.2	2 Respirator policy	8		
	2.1.3	3 Vaccination policy	9		
	2.2	Future variant scenarios	10		
	2.2.2	1 Timing of arrival	10		
	2.2.2	2 Transmissibility	11		
	2.2.3	3 Virulence	11		
	2.2.4	1 Immune escape	17		
3	Vaco	cine effectiveness and protection against reinfection	18		
	3.1	Vaccine effectiveness	18		
	3.2	Protection from reinfection	24		
	3.3	Hybrid immunity	27		
	3.4	The effect of immunity on onward transmission	28		
4	Mor	bidity and mortality estimates	28		
	4.1	Acute COVID-19 morbidity	28		
	4.2	Long COVID morbidity	32		
	4.3	Longer term consequences of SARS-CoV-2 infection	38		
	4.4	Mortality	39		
5	Ecor	nomic analyses	41		
	5.1	Testing costs	41		
	5.2	Acute COVID-19 morbidity expenditure	41		
	5.3	Long COVID morbidity expenditure	43		
	5.4	Intervention costs	47		
	5.5	GDP costs of stages of PHSMs	49		
	5.6	Unrelated disease costs	49		
6	Refe	rences	52		

1 AGENT-BASED MODEL

1.1 Overview and input parameters

We used an agent-based model (ABM) with 2,500 agents and a daily cycle length. Each agent was assigned attributes including age (in 10-year strata), essential worker status, and a household. Depending on the scenario, agents were also proportionally assigned vaccine, mask usage, and other characteristics. Each day, agents move around the 2-dimensional model space, with all infected agents having a chance to infect susceptible agents at their location.

The model space contains gathering locations, which all agents have a higher probability of visiting, and home locations that are frequently visited by members of each household. Agent movement includes returning to their household, moving around the community, visiting nearby gathering locations, "superspreading" (by jumping to a random gathering location), and the possibility of noticing the presence of other agents and attempting to avoid them. The weights of various types of movement depend on the public health measures in place at any given time, as well as heterogeneity in agent behaviour (with a large age component). Agents tracked in the contact tracing system, or those who notice their own symptomatic infection, have a high chance of isolating by staying home and reducing their infectivity.

At the end of the movement phase, each infectious agent has a chance to infect each non-infected agent at its location. The probability of transmission depends on the infectiousness and susceptibility of the two agents involved. The infectiousness of an agent increases linearly to a maximum up to their peak infectivity time, then linearly decreases to zero (Appendix Table 1). Infectiousness is also modified by whether the agent wears a mask, whether they are symptomatic, and whether they try to isolate. These parameters have per-agent draws for heterogeneity. Susceptibility to infection is modified by waccine status and recovery from previous infection, dependent upon on the type of vaccine received (or the variant responsible for previous infection), the variant responsible for exposure, and waning since vaccination or previous infection.

The model simulates the population of Victoria using only 2,500 agents by scaling. Each infected agent represents a number of people, with this number inherited from the agent that infected them. Infected

agents are split or merged with similar agents when there are too few or too many infected agents in the model. The model attempts to maintain between 130 and 150 infected agents, except when the number of infections reaches the upper or lower scale bounds of the model. At low scales the model essentially operates by zooming in on the part of Victoria where infection is spreading, while being able to scale up to simulate all of Victoria in a large wave. By scaling up and down, the impact on the total number of infected, vaccination, recovered, etc., people in a population the size of Victoria (6.6 million) was tallied and retained. These metrics dynamically determine public health measures and community carefulness in the model.

Input parameters have probability distributions from which values are drawn for each of the 100 iterations of the Monte Carlo analysis in the ABM. Key ABM input parameters are shown in Appendix Table 1. All variables (except the last 'carefulness' parameter) were specified a priori and not subject to amendments in calibration. The values of the 'carefulness' parameter were set in calibration (see next section). Within each iteration, there was an inner loop of four stochastic iterations; with just 2,500 agents in the ABM, the stochastic uncertainty for the Victorian population likely overestimated. Under a normal distribution approximation the average output value (e.g., number of infections) over four stochastic runs will halve the standard deviation attributable to stochastic uncertainty (1/v4 = 0.5).

Parameter	Estimate				
Agent infectivity	The infectiousness on each day of the agent's infection is set to approximate data on Delta, ¹ parameterised by agent-level draws for peak infectivity, time to peak infectivity, and illness duration. The infectivity of an agent on a given day is determined by linearly interpolating:				
	 10% of their peak infectivity on day 0, their full peak infectivity at their time to peak infectivity, and zero at their illness duration. 				
Time to peak infectivity (days)	Per-agent log normal distribution: mean = 4.4, SD = 1.5 ¹				
Illness duration (days)	Normal distribution: Mean = 10.9, SD = 2 (time to peak infectivity ¹ plus estimated duration of active disease ²)				
Mean adherence with isolation of infected cases	Global beta distribution (beta 450.3, 23.7; mean = 95%, SD = 1%)				
Infectiousness of asymptomatic v. symptomatic cases per contact	RR 0.58 (95% CI 0.34 to 0.99) ³ (parameterised as a log normal distribution with median = -0.545 and SD = 0.270)				
Household size	Beta distribution with median = 3. Beta 2.2, 2.2 scaled to [1, 5], draws rounded to nearest integer				
Proportion of non-household contacts traced within the first three days, at a caseload of 5 per day.	0.9				

Parameter	Estimate
Chance of an infected non- household contact of a known case becoming known through contact tracing, per day.	Chance = 1 / (dailycases * ((a * dailycases ^{0.92} – b) + 100)), where dailycases = known daily cases averaged over the last week. Solved for a and b with (dailycases, chance) = (1, 0.729) and (5, 2.679). This traces 90% and 98% of contacts at a caseload of 5 and 1 per day respectively. The expected number of cases traced per day asymptotes at 100.
Chance of an infected household contact of a known case becoming known, per day.	100%
Proportion of undetected symptomatic cases who spontaneously reported themselves	Beta 6,6
Time for undetected symptomatic cases spontaneous self-reporting	1-2 days after peak infectivity
Transmission multiplier of person who is complying with their isolation	0.33
Relative susceptibility to infection, by age (OR for infection given exposure)	0 – 9 years: 0.34 10-19: 0.67 20 – 59 years: 1 60-69: 1.23 ≥70 years: 1.47 ⁴ Uncertainty on all values +/- 15% SD
Relative 'carefulness' multiplier to susceptibility, by age	0 - 9 years: 2.09 10 - 19 years: 1.34 20 - 49 years: 1 50 - 59 years: 0.84 60 - 69 years: 0.51 70 - 79 years: 0.24 80 - 89 years: 0.22 ≥90 years: 0.21 Uncertainty on all values +/- 15% SD

1.2 ABM calibration

Having set a priori variables as per Appendix Table 1, we calibrated the model to achieve R₀s of 10, 12, 13 and 15 (see Transmissibility section below) in a situation with no vaccination, previous infection, contact tracing, or public health and social measures (PHSMs). R₀s were found by introducing a single infected agent into the naïve population and counting infections caused by case zero, 4000 times. The key variable 'tuned' was the base transmissibility of the virus, i.e., the probability of a single average interaction between an infected agent and susceptible agent resulting in infection of the susceptible agent. Spatial parameters were also adjusted to allow for a range of transmissibility values to achieve the required R₀s.

We then used a separate model to initiate the infection and vaccination status of the 2,500 agents by approximating vaccination, time since vaccination, and cumulative infection with variation by age as in Victoria on 1 April 2022 (Appendix Table 2). Infections were randomly assigned to agents, with less probability for those who were vaccinated (and allowing for waning vaccine immunity over time using a previously published logistic regression equation discussed in greater detail below).⁵ No single-vaccinated agents were modelled. Pre-Omicron past infection was uncommon in Victoria and was ignored. Transmissibility was drawn uniformly from the range corresponding to R₀s 10 and 12. The proportion of previously infected agents was set to double that of reported cases in Victoria to allow for under-notification.⁶

With R₀ calibrated and baseline infection and vaccination status of agents assigned, we then iteratively calibrated the PHSMs in Stage 2 to achieve, over an average of 1,000 runs, 1.2 million infections in the 60 days following the 1st of April 2022. This corresponds to an average of 20,000 infections per day, which is twice the average daily reported cases in this period to allow for under-notification. In parallel, the 'carefulness' parameter in Appendix Table 1 was adjusted to achieve the age distribution of infections occurring in Victoria in the same period (Appendix Table 3). The 'carefulness' parameter is – we argue – theoretically justified, in that as the pandemic has evolved citizens are increasingly dynamically responding to infection rates likely in an age-dependent manner (e.g., working-age individuals working from home and avoiding public transport when infection rates are high, elderly people at highest risk of severe illness being particularly cautious to avoid infection).

Age % distribution of		% double vaccinated as	% triple vaccinated as	Cumulative infection as
(years)	population	of 1 April 2022	of 1 April 2022	of 1 April 2022
0-4	5.7%	-	-	32.0%
5-11	8.7%	30.2%	-	34.5%
12-17	6.9%	95.6%	12.4%	45.6%
18-29	16.5%	87.1%	44.5%	48.8%
30-39	15.5%	93.8%	56.2%	40.3%
40-49	12.8%	96.4%	68.2%	34.7%
50-59	12.0%	96.4%	74.4%	25.7%
60-69	10.2%	97.1%	81.1%	17.2%
70+	11.6%	98.8%	88.1%	11.3%

Appendix Table 2: Age, vaccination status and cumulative infection of the 2,500 initiating agents in the ABM

All	-	83.5%	53.1%	32.9%
-----	---	-------	-------	-------

Appendix Table 3: Calibration target of infections by age, 60 days following 1 April 2022

Age (years)	Target distribution of infections by age
0-9	12.50%
10-19	13.00%
20-29	14.10%
30-39	18.90%
40-49	15.30%
50-59	11.80%
60-69	7.80%
70-79	4.30%
80-89	1.80%
90+	0.60%

2 MODELLED SCENARIOS

2.1 Policy options

2.1.1 Suppression policy

Following calibration, the PHSMs associated with each stage were defined as shown in Appendix Table 4. The ABM cycled between these stages based on predicted pressure on health service infrastructure (defined by the predicted number of people hospitalised) and two suppression strategy policy options – higher and lower stringency – which aimed to keep peak hospital occupancy less than 200 and 400 per million residents respectively as per the (de)escalation rules in Appendix Table 5. The behaviour of agents was also dynamic based on infection incidence, to reflect the public modulating their interactions in response to outbreaks independent of government-imposed restrictions.

Ar	ppendix	Table 4	: Kev	input	parameters b	v stage of	public	health and	l social	measures
~	pendix		• IXC y	mput	parameters b	y stage of	public	incartin and	1 30010	measures

	Stage 1	Stage 2	Stage 3	Stage 4	Stage 5
Proportion of people who try to avoid contact with others (excluding their household) ^{†*}	35%	53%	63%	75%	85%
Proportion of time spent trying to avoid contacts, for those that attempt to do so ^{†*}	45%	63%	73%	83%	90%
Proportion of workers attending work in person ⁺	70%	51%	35%	20%	10%
Schools open (disable contact avoiding behaviour among students)	Yes	Yes	Yes	No	No

Proportion of people that wear masks outside the $home^{\dagger}$					
≥20-year-olds	20%	35%	60%	80%	90%
10- to 19-year-olds	16.7%	26.67%	40%	53.3%	60%
<10-year-olds	11.1%	17.78%	26.67%	35.6%	40%
Proportion of mask wearing that is with a respirator#					
No government supply	20%	20%	20%	20%	20%
Government supply policy active	20%	20%	80%	80%	80%
Proportion of people that engage in super spreading behaviour each day (move to a random gathering location) ⁺	5%	3.5%	2.2%	1.6%	1%
Underlying frequency of visiting a random nearby gather location each day (e.g., a supermarket)	14.28%	14.28%	13%	7.5%	5%
Radius for determining whether a gather location counts as nearby	8.8	6.7	6	5	3.6
Maximum distance moved by an agent each day	12	9	7.5	6	5

[†]ORs of 2, 4, 6 and 8 are applied to the proportion of people that wear a mask, isolation compliance (Appendix Table 1) proportion of people that avoid others, and proportion of time spent avoiding others for those aged 50-60, 60-70, 70-80 and \geq 80 respectively to capture increasing infection avoidance behaviour in older age groups. Reciprocals of these ORs are applied to the daily chance of visiting a gather location, and daily chance of superspreading. Note agents \geq 60 years old are excluded from the category of workers.

*In stages 1-3, the proportion of people who try to avoid contact with others and the proportion of time spent trying to avoid contacts for those attempting to do so are dynamic, based on the average number of infections over the last 7 days. Proportions are as written above if the 7-day average of infections is <5000. Proportion of people who try to avoid contacts and proportion of time spent avoiding increase to a maximum of 15 and 10 percentage points higher than those written above, respectively, at 32,000 daily infections over the last seven days. The region between 5000 and 32,000 is linearly interpolated. #Only applies to those aged \geq 10 years.

Appendix Table 5: Triggers for escalation and de-escalation of stages of public health and social measures, by suppression policy

Suppression policy	Triggers
Triggers for <i>lower stringency</i> suppression policy	EscalationIf average expected number of people in hospital due to COVID-19 10-14days (inclusive) into the future is:->600 per million \rightarrow Stage 5->400 per million \rightarrow Stage 4->270 per million \rightarrow Stage 3->180 per million \rightarrow Stage 2De-escalationIf no de-escalation in last 7 days, and average expected number ofpeople in hospital 10-14 days (inclusive) into the future is:-<450 per million \rightarrow Stage 4 if in Stage 5-<300 per million \rightarrow Stage 3 if in stage 4 or 5-<200 per million \rightarrow Stage 2 if in Stage 3, 4 or 5-<140 per million \rightarrow Stage 1
Triggers for <i>higher stringency</i> suppression policy	Escalation: If average expected number of people in hospital 10-14 days (inclusive) into the future is: - >300 per million → Stage 5

- >200 per million → Stage 4 - >130 per million → Stage 3 - >90 per million → Stage 2
De-escalation:
If no de-escalation in last 7 days, and average expected number of people in hospital 10-14 days (inclusive) into the future is: - <230 per million → Stage 4 if Stage 5 - <150 per million → Stage 3 if in stage 4 or 5 - <100 per million → Stage 2 if in Stage 3, 4 or 5 - <70 per million → Stage 1

2.1.2 Respirator policy

At the time of writing, masks were no longer mandated in most indoor settings in Victoria but were still recommended. Masks remained mandatory on public transport, on aircraft, in health care settings, and if a close contact of a COVID-19 case. These regulations, however, do not specify the type of mask that the public should use. We modelled the maintenance of a stockpile of 10 respirators per person for the whole Victorian population aged 10 years and older, that are distributed for use at four-week intervals (rotating masks on a five-day cycle with extra masks to cover for spoilage) if in stage 3 or higher. In essence, this changes the proportion of people wearing respirators from 20% at baseline to 80% (Appendix Table 4) in these stages while the respirator policy is active.

There is a paucity of high-quality evidence providing estimates of the degree of protection afforded by mask-wearing at the individual level in community settings for the transmission of SARS-CoV-2. A recent systematic review and meta-analysis⁷ that examined the effectiveness of public health measures in reducing the incidence of COVID-19 reported a relative risk of infection of 0.47 (95% CI 0.29 to 0.75) associated with mask-wearing overall, based on six studies. The authors note, however, a high degree of heterogeneity between these studies and substantial risk of bias. In a World Health Organization-commissioned systematic review and meta-analysis published in 2020, protection afforded by wearing an N95 mask or "surgical or similar" mask was estimated at 95% (95% CI 34% to 100%) and 58% (95% CI 24% to 77%) respectively. This review, however, included literature regarding three betacoronaviruses (MERS-CoV, SARS-CoV and SARS-CoV-2) and studies in both healthcare and community-based settings,^{8,9} limiting applicability to our model.

We elected to base our estimates of mask effectiveness on a recently published test-negative casecontrol study enrolling individuals receiving COVID-19 test results from February to December 2021 in California, USA, which provides estimated effect sizes for protection stratified by type of mask.¹⁰ Estimates were adjusted for vaccination status, household income, race/ethnicity, age, sex, state region and county population density. The primary analysis assessed self-reported mask use in indoor public settings during the 14 days preceding testing between those receiving positive and negative SARS-CoV-2 test results and found adjusted odds of infection of 0.44 (95% CI 0.24 to 0.82) associated with always using any type of mask or respirator. Adjusted odds for infection associated with using cloth masks, surgical masks and respirators were 0.44 (95% CI 0.17 to 1.17), 0.34 (95% CI 0.13 to 0.90) and 0.17 (0.05 to 0.64) respectively. Assuming 5% of 'always' mask use was N95 masks, these reported estimates were adjusted to the following for use in our model:

- Cloth/surgical masks: odds ratio (OR) 0.468 (or -0.76 on ln scale, with SD 0.31)
- N95 respirators: OR 0.204 (or -1.59 on ln scale, with SD 0.65)

We specified 100% correlation on draws of mask effectiveness and assumed the same risk reduction in onward transmission if wearing a mask.

2.1.3 Vaccination policy

Australia had a mixed rollout of mRNA-based COVID-19 vaccines (BNT162b2 and mRNA-1273) and an adenovirus vector-based vaccine (ChAdOx1) for the primary series and predominantly mRNA-based vaccines for further boosting. In our model, we combined all currently available vaccines into one generic 'current generation' vaccine with effectiveness as outlined below. We then specified two types of 'next generation' vaccines with vaccine effectiveness (VE) expected to be superior to currentgeneration vaccines against emerging variants to reflect advances in vaccination technology – (i) Omicron-targeted vaccines that specifically target one or more subvariants of Omicron and (ii) multivalent vaccines that confer broader spectrum protection against several variants or viruses (e.g., by targeting more conserved regions of the virus or targeting the spike protein of multiple variants within a single vaccine formulation). Examples of Omicron-targeted vaccines include monovalent candidates developed by Moderna (mRNA-1273.529) and by Pfizer and BioNTech, both targeting the BA.1 subvariant of Omicron.^{11,12} Examples of multivalent vaccines include the Spike Ferritin Nanoparticle vaccine developed by the Walter Reed Army Institute of Research¹³ and Vaxart's oral formulation, VXA-CoV2-1.^{14,15} Both Moderna and Pfizer are also developing Omicron BA.1-adapted bivalent formulations that have shown superiority over current-generation vaccines in early human trials.^{12,16} Given that next generation efficacy data is sparsely available, these vaccines are conjectured to have likely VE against emerging Omicron-like variants and novel variants as outlined below.

We specified 11 hypothetical vaccination schedules as shown in Appendix Table 6. These were informed by current vaccination policy discussions in the Australian context, including debate regarding the value of a fourth current vaccine dose for the general public, the potential value of delaying this to await the arrival of next generation vaccines (e.g., scenario d), and the value of targeting boosters to older individuals (scenarios g to k).

Scenario	Apr-Jun 2022	Jul-Sep 2022	Oct-Dec 2022	Jan-Mar 2023	Apr-Jun 2023	Jul-Sep 2023
a) Nil further						
b) 3 Current generation (CG)*		CG		CG		CG
c) 1 CG, then 2 omicron-targeted (OT)*		CG		ОТ		ОТ
d) 2 OT only*			ОТ		OT	
e) 1 CG then 2 multivalent (MV)*		CG		М		М
f) 2 MV only*			М		М	
g) 3 CG (≥60 years)		CG		CG		CG
h) 1 CG, then 2 OT (≥60 years)		CG		ОТ		ОТ
i) 2 OT only (≥60 years)			ОТ		OT	
j) 1 CG then 2 MV (≥60 years)		CG		М		М
k) 2 MV only (≥60 years)			М		М	

Appendix Table 6: Eleven vaccination schedules treated as policy options

*Applies to \geq 20-year-olds with triple dose coverage and <20-year-olds with double dose coverage on 1 April 2022. At each wave of vaccination, it is assumed that 80% of people (+/-10% SD, beta distribution) vaccinated in the last wave take up the new offering. For example, 80% of \geq 20-year-olds who start the model on 1 April 2022 already triple-vaccinated receive the next dose of the scheduled vaccine. \geq 20-year-olds who had not received their third dose by 1 April 2022 do not receive any further vaccines. Vaccine rollout is even over three months with no prioritization by age.

2.2 Future variant scenarios

We specified 64 future SARS-CoV-2 variant scenarios, formed by cross-classifying timing of arrival (4 options), transmissibility (2 options; R_0 11 and 14), virulence (2 options; low and high), type of variant (2 options; antigenically Omicron-like and novel) and associated immune escape capacity (2 options, depending on transmissibility and antigenic similarity to Omicron); these are outlined below.

2.2.1 Timing of arrival

We set four alternative dates for the arrival of a new variant into Victoria: July 2022, October 2022, January 2023 or April 2023 (implemented in 91-day increments from 1 April 2022; i.e., 91, 182, 273 and 364 days into the model run). This was incorporated by a 2% chance of newly infected people spontaneously receiving the new variant applied to every infection event after the incursion date.

2.2.2 Transmissibility

The model is calibrated to produce R_0s of 11 (uniform distribution 10 to 12) for variants with lower intrinsic transmissibility and 13 (uniform distribution 12 to 14) variants with higher innate transmissibility. The target R_0 of 11 was selected to approximate Omicron BA.2 – reported R_0 values for this variant vary and are debated in the literature. As such we used an estimate reported in an analysis and commentary by Australian epidemiologists.¹⁷

2.2.3 Virulence

Hopes that future variants of concern will incrementally lose virulence as occurred with the Omicron variant are unfounded; virulence arises largely independent of a variant's ability to transmit or evade the immune response.^{18,19} Accordingly, new variants were characterized as either high or low (approximating Omicron) virulence. We first specified low virulence by calibrating international estimates to the Victorian Omicron wave experience in April and May 2022, as outlined below. For the high virulence variant, we assumed 4¹= 4, 4^{0.75}= 2.83, 4^{0.5}= 2 and 4^{0.25}= 1.41 ratio increases in the infection fatality risk (IFR), risk of ICU admission, risk of hospital admission, and risk of being symptomatic, respectively, compared to low virulence variants.

2.2.3.1 Infection fatality risk

We fitted a logistic regression model to Institute for Health Metrics and Evaluation (IHME) estimates of age-specific IFRs (\geq 10 years of age) for the ancestral strain of SARS-CoV-2 (Table 1 of ²⁰). This gave a coefficient of 0.1049 for age in years. We then used this age variation in the calibrated ABM applied to 60 days post 1 April 2022 in Victoria that included vaccination status and prior infection status of agents. An intercept or constant of -11.9861 for the equation predicting IFR among the unvaccinated and previously uninfected output the number of deaths actually observed in Victoria during these 60 days when the model was generating 20,000 infections per day (see calibration section above). The final IFR equation is shown below, as well as that similarly set as a constant IFR among the unvaccinated and previously uninfected for <10-year-olds. The equation for the high virulence variant simply had ln(4) = 1.3863 added (i.e. to achieve four-fold higher IFRs for more virulent variants).

- Current Omicron and low virulence new variant:
 - ≥10 years: logit(IFR) = 0.1049*age 11.9861 (SD = 0.205)
 - o <10 years: logit (IFR) = -11.6051 (SD = 0.269)</p>
- High virulence new variant:
 - ≥10 years: logit(IFR) = 0.1049*age 10.5999 (SD = 0.205)

<10 years: logit(IFR) = -10.2189 (SD = 0.269)

IFRs for unvaccinated and previously uninfected people, for low and high virulence variants, are shown in Appendix Figure 1. These IFRs are then modified according to vaccination and previous infectious status (with waning) for each agent in the ABM as outlined below.



Appendix Figure 1: IFRs among unvaccinated and previously uninfected individuals, for low and high virulence variants

2.2.3.2 ICU admission risk

To obtain the age-dependent probability of ICU admission given infection, we used the age gradient published by Knock et al. for ancestral SARS-CoV-2.²¹ For those aged \geq 30 years the probability of ICU admission given infection increases approximately linearly by age on a logarithmic scale, described by the equation logit(ICU | inf) = 0.1293*age – 12.866. Risks in Knock et al. of ICU admission given infection on the logarithmic scale for those aged 0 to 9 years and 10 to 29 years were -9.2629 and -10.4237 respectively. ICU admission risk beyond 80 years was set as that for an 80-year-old. We then reduced ICU admission risk for those aged 80-89 years by 25% and those aged \geq 90 years by an additional 75% to reflect a lower likelihood of ICU admission in older age despite clinically severe disease.

These estimates were then adjusted during calibration (similarly to that above for IFR) for a lowvirulence variant (approximating Omicron) to achieve the number of COVID-19-related ICU admissions in Victoria from 1 April to 30 May 2022 (on a background of vaccination and previous infection rates approximating that in Victoria during this period). We then applied a 4^{0.75}= 2.83 ratio difference in ICU admission risk between the low and high virulence variants to give the following:

- Current Omicron and low-virulence new variant:
 - ≥90 years: logit(ICU | inf) = 0.129*age 13.386 (0.481+1.386) 0.266 (SD = 0.1)
 - 80-89 years: logit(ICU | inf) = 0.129*age 13.386 (0.481 + 0.288) 0.266 (SD = 0.1)
 - 30-79 years: logit(ICU | inf) = 0.129*age 13.386 0.481 0.266 (SD = 0.1)
 - 10-29 years: logit(ICU | inf) = -10.943 0.481 0.266 (SD = 0.1)
 - <10 years: logit(ICU | inf) = -9.783 0.481 0.266 (SD = 0.1)
- High-virulence new variant:
 - ≥90 years: logit(ICU | inf) = 0.129*age 12.346 (0.481+1.386) 0.266 (SD = 0.1)
 - 80-89 years: logit(ICU | inf) = 0.129*age 12.346 (0.481 + 0.288) 0.266 (SD = 0.1)
 - 30-79 years: logit(ICU | inf) = 0.129*age 12.346 0.481 0.266 (SD = 0.1)
 - 10-29 years: logit(ICU | inf) = -9.904 0.481 0.266 (SD = 0.1)
 - <10 years: logit(ICU | inf) = -8.743 0.481 0.266 (SD = 0.1)

The resultant infection ICU admission risks for unvaccinated and previously uninfected people, for low and high virulence variants, are shown in Appendix Figure 2. These risks are then modified according to vaccination and previous infectious status (with waning) for each agent in the ABM.





2.2.3.3 Hospitalisation risk

To obtain the age-dependent probability of hospitalization given infection, age-variation is also based on data published by Knock et al.²¹ For individuals aged \geq 30 years, the Knock et al. probability of hospitalization given infection increases approximately linearly by age on a logarithmic scale, described by the equation logit(hosp | inf) = 0.0997*age – 8.9113. For people younger than 30 years the risk of hospitalization given infection is not linear on the logarithmic scale and as such averages of point estimates were used (-6.0308 for those aged 0 to 9 years and -7.1235 for those aged 10 to 29 years).

These estimates were then calibrated for a low-virulence variant (approximating Omicron, and as above for IFR and ICU) to achieve the number of COVID-19-related hospital admissions in Victoria from 1 April to 30 May 2022. We applied a $4^{0.5}$ = 2 ratio difference in hospitalisation risk between the low and high virulence variants to give the following:

• Current Omicron and low-virulence new variant:

- ≥30 years: logit(hosp | inf) = 0.0997*age 9.258 0.601 (SD = 0.1), capped at risk for an 80-year-old (i.e. constant hospitalisation risk for those aged 80 years and older)
- 10-29 years: logit(hosp | inf) = -7.470 0.601 (SD = 0.1)
- <10 years: logit(hosp | inf) = -6.377 0.601 (SD = 0.1)</p>
- High-virulence new variant:
 - ≥30 years: logit(hosp | inf) = 0.0997.age 8.5647 0.601 (SD = 0.1), capped at risk for an 80-year-old
 - 10-29 years: logit(hosp | inf) = -6.777 0.601 (SD = 0.1)
 - <10 years: logit(hosp | inf) = -5.684 0.601 (SD = 0.1)</p>

The resultant infection hospitalisation risks for unvaccinated and previously uninfected people, for low and high virulence variants, are shown in Appendix Figure 3. These risks are modified according to vaccination and previous infectious status (with waning) for each agent in the ABM.





2.2.3.4 Symptomatic infection risk

Estimates regarding the probability of being symptomatic given infection with SARS-CoV-2 were based on those from a meta-analysis using data through to April 2021.²² These were then multiplied $2^{0.25}$ and $0.5^{0.25}$ to obtain estimates of the probably of symptomatic disease given infection on an OR scale for a more or less virulence variant respectively, to give the following (converted back to a percentage scale; uncertainty +/-10% SD on log odds scale for all values):

- Current Omicron and low-virulence new variant:
 - \geq 60 years: Pr(symptomatic | inf) = 0.774
 - 20-59 years: Pr(symptomatic | inf) = 0.640
 - <20 years: Pr(symptomatic | inf) = 0.490
- High-virulence new variant:
 - \geq 60 years: Pr(symptomatic | inf) = 0.829
 - 20-59 years: Pr(symptomatic | inf) = 0.716
 - <20 years: Pr(symptomatic | inf) = 0.576

2.2.3.5 Length of hospital and ICU stay

Variant virulence impacted length of hospital and ICU stay as shown in Appendix Table 7, with estimates based on those for New South Wales, Australia, during periods of Delta and Omicron predominance.²³

	Age (vears)	Omicron/low virulence variant	High virulence variant (LOS,
	Age (years)	(LOS, days)	days)
	≤39	2.05 (1.80 to 2.30)	3.60 (3.48 to 3.81)
Hospital LOS	40-69	2.92 (2.50 to 3.67)	5.78 (5.59 to 5.99)
	≥70	6.02 (4.91 to 7.01)	12.31 (11.75 to 12.95)
	≤39	3.93 (2.58 to 5.68)	7.50 (6.99 to 8.33)
ICU LOS	40-69	4.30 (3.29 to 5.72)	9.44 (8.81 to 10.07)
	≥70	4.36 (3.40 to 5.57)	8.94 (7.80 to 9.91)

Appendix Table 7: Mean (and 95% confidence interval) length of stay associated with low and hi	gh
virulence SARS-CoV-2 variants	

LOS: length of stay. Uncertainty around these values parameterised in the model using a normal draw with a standard deviation

based on the width of the reported 95% confidence interval divided by 3.92

2.2.4 Immune escape

SARS-CoV-2 is under strong evolutionary pressure to develop mutations that afford it the ability to escape pre-existing immunity, either obtained through vaccination or previous infection.¹⁹ We reflected this in our model via ORs applied to agent immune protection at any given point in time (either vaccine-or natural infection-derived; see below for details regarding calculation of protection).

For the Omicron variant, both next-generation Omicron-targeted and multivalent vaccines were assumed to boost VE by an OR of 2 compared to current-generation vaccines. That is, we assume that a next-generation multivalent vaccine incorporates the benefits of a next-generation Omicron-targeted vaccine. For emerging variants that have the same innate transmissibility as Omicron, they are likely to require some capacity for immune escape to become the dominant circulating strain. As such, we modelled moderate and large immune escape capacity for these variants using the ORs in Appendix Table 8, with variation based on whether the variant is antigenically like Omicron or novel. For new variants that have higher innate infectiousness, no immune escape is required to have a survival advantage. Hence, we model nil and moderate immune escape for these variants using the ORs in Appendix Table 8 also with variation based on whether the variant is antigenically like Omicron or novel. Immune escape also applies to immunity following natural infection as shown in Appendix Table 9.

		Current generation double dose	Current generation 3+ doses	Next-gen Omicron- targeted 1+ doses	Next-gen multivale nt 1+ doses
	Current Omicron (BA.2)	1 (ref)†	1 (ref) [‡]	2	2
New variants with same innate infectiousness as Omicron BA 2 ($B_0 = 11$ range 10 to 12)	Omicron-like variant	0.707, 0.5	0.707, 0.5	1.414, 1	1.414, 1
as officion balz (N) = 11, range 10 to 12,	Novel variant	0.707, 0.5	0.707, 0.5	1, 0.707	1.414, 1
New variants with higher innate infectiousness than Omicron BA.2 (R ₀ = 14,	Omicron-like variant	1, 0.707	1, 0.707	2, 1.414	2, 1.414
range 13 to 15)	Novel variant	1, 0.707	1, 0.707	1.414, 1	2, 1.414

Appendix Table 8: Immune escape odds ratios for vaccines cross-classified by variants in the model

†Reference for the current generation double dose column.

‡Reference for the current generation triple dose, next-generation omicron-targeted and next-generation multivalent columns. These ORs apply at any point in time, with waning post last dose also in effect. All italicized ORs are drawn from a range of 0.841 to 1.189 of their stated values, with 100% correlation (including the OR of 2 for next-generation vaccines against current Omicron) uniformly on the log OR scale. For each combination of vaccine and variant, 2 levels of possible immune escape are modelled.

Appendix Table 9: Immune escape odds ratios for natural protection following primary infection crossclassified by variants in the model

		Previous infection with Omicron	Previous infection with new variant
	Current Omicron (BA.2)	1 (ref)	1, 1
New variants with same innate infectiousness as Omicron BA.2 (Ra = 11, range 10 to 12)	Omicron-like variant Novel variant	0.707, 0.5 0.707, 0.5	1, 1 1, 1
New variants with higher innate infectiousness than Omicron BA.2 (R ₀ = 14, range 13 to 15)	Omicron-like variant Novel variant	1, 0.707 1, 0.707	1, 1 1, 1

These ORs apply at any point in time, with waning post previous infection also in effect. All italicized ORs are drawn uniformly from a range of 0.841 to 1.189 of their stated values, with 100% correlation, uniformly on the log OR scale. For each combination of previous/current variant, 2 levels of possible immune escape are modelled.

3 VACCINE EFFECTIVENESS AND PROTECTION AGAINST REINFECTION

3.1 Vaccine effectiveness

The effectiveness of COVID-19 vaccines peaks soon after receipt of a full vaccination course and wanes in a non-linear fashion thereafter.²⁴⁻²⁶ To dynamically model waning of vaccine-derived immunity for the outcomes of symptomatic infection and hospitalisation from COVID-19, we developed a log-odds system of equations that has been published elsewhere⁵ building on VE data published by the UK Health Security Agency (UKHSA).^{24,27} In summary, a random effects logistic regression model with a separate class for each combination of vaccine course and outcome was fitted to this data, excluding observations within 2 weeks since last vaccine dose (given peak immunity would still have been developing) and weighted by the inverse variance as follows:

 $logit(VE) = \alpha + \beta_1 Hosp + \beta_2 Triple + \beta_3 Month + \beta_4 Hosp * Month + \beta_5 Triple * Month$

where:

VE is vaccine effectiveness;

lpha is the intercept, or the logit of the VE for the reference case (VE against symptomatic illness two weeks after double dose vaccine);

Hosp is a dummy variable for hospitalisation versus symptomatic illness;

Triple is a dummy variable for triple versus double vaccine course;

Month represents months (continuous) since last vaccine dose minus 0.5 (i.e., 'centered' on two weeks post the last vaccine dose to aid interpretation of model coefficients);

*Hosp*Month* is an interaction term of hospitalisation and month (i.e., how VE wanes differently on the In odds scale for protection against hospitalisation as compared to protection against symptomatic illness); and

*Triple*Month* is an interaction term of triple and month.

For models including interaction terms of *hosp*triple*month* and *triple*hosp* these coefficients had nonsignificant p values, and the differences in deviance statistics between these models and that without these interaction terms were trivial and non-significant. As such they were not retained in the final model.

The UKHSA data used to develop the random effects logistic regression model described above did not include VE estimates stratified by age. However, there is evidence that VE varies by age.²⁵ To alter the regression equation to reflect this, we focused on estimates at 10-14 weeks post-vaccination. Using data from a study reporting VE against the Delta variant stratified by age group (\geq 16 years, 16-39 years, 40-64 years, \geq 65 years) and vaccine type (ChAdOx1-S or BNT162b2)²⁵ we specified the following:

- The VE OR for ≥65-year-olds compared to <65-year-olds for BNT162b2 VE against symptomatic disease was 0.77 (at 10-14 weeks after receipt of a second dose).
- The VE OR for ≥65-year-olds compared to <65-year-olds for BNT162b2 VE against hospitalization was 0.36 (at 10-14 weeks after receipt of a second dose).
- The proportion of symptomatic cases in the <65-year-old group was 94%, and the proportion of hospitalisations in the <65-year-old group was 70.2%.

To fit these data, the above logistic regression model was re-estimated to preserve VE at 3 months postvaccination, by solving for a new intercept. Further adjustments were then made to generate coefficients split by 3 age strata; <60 years, 60-69 years, and \geq 70 years (to fit the 10-year age strata specified in our ABM).

Next, we extended the above logistic regression model to account for the outcomes of any infection (including asymptomatic infection), ICU admission and death. The UKHSA reports VE (all vaccines combined) for mortality against the Omicron variant for those aged \geq 50 years to be 95% at \geq 2 weeks following receipt of a third dose.²⁸ By combining this estimate with their reported OR for symptomatic disease \geq 2 weeks after 3 doses for the same age group (0.41) and the associated 95% confidence intervals we drew 5,000 estimates of the odds VE of mortality v. symptomatic disease, the median of which was used to estimate a coefficient for the outcome of death in the overall VE logistic regression equation. Whilst these input data were for \geq 50-year-olds who were triple-dose vaccinated, given we do not allow for interactions of age with severity and triple dose with severity we could use estimates at any age to estimate the 'independent' or 'main' effect for VE protection against death.

Limited data is available to inform estimates of VE against any infection with the Omicron variant (i.e., asymptomatic and symptomatic infection combined). As such, data from the UK Vaccine Effectiveness Expert Panel²⁸ were used to estimate the odds ratio for VE for all infections compared to the VE for symptomatic infection at 3 months (for BNT162b2 and mRNA-1273) and obtain the coefficient for any infection. Specifically, for each of the four combinations of BNT162b2 and mRNA-1273, for two and three doses:

- the values reported in Table 3 of the UKHSA Week 13 COVID-19 Vaccine Surveillance Report²⁹
 (VE as a percentage with a range both for any infection and symptomatic infection) were converted to logit(VE) with mean = In odds of central VE, and SD = range/3.92 (approximating the 95% uncertainty interval).
- 5,000 draws on the ln odds scale were taken of each of 'any infection' and 'symptomatic infection', with 0.5 correlation between the two values.
- The median and 2.5th and 97.5th percentiles of the ln odds VE were determined.

The final coefficient for any infection was the average of the four In odds VE values (-0.78), and the final SD (on the In odds scale) was the average of the SD (assumed as 97.5th percentile – 2.5th percentile, divided by 3.92; 0.27). For the outcome of ICU admission, the coefficient was estimated as the mid-point between the coefficients for hospitalization and death, with the same standard deviation as that for death. The final VE equation utilized in the ABM was therefore defined as follows:

$logit(VE) = \alpha + \beta_0 Age + \beta_1 Severity_j + \beta_2 Triple + \beta_3 Month + \beta_4 Severity * Month + \beta_5 Triple$ * Month

where:

 α is the intercept or the logit of the VE for the reference case (<60 years old, two doses of vaccine, against symptomatic infection, 2 weeks after the last dose); *Age* is a categorical variable of \geq 70 years, 60-69 years, or <60 years (ref); *Severity* is categorical value of any infection, symptomatic infection (ref), hospitalisation, ICU admission or death;

Triple is a dummy variable for triple versus double vaccine course;

Month represents months (continuous) since last vaccine dose minus 0.5 (i.e., 'centered' on two weeks post the last vaccine dose to aid interpretation of model coefficients);

Severity*Month is an interaction term of severity and month; and

*Triple*Month* is an interaction term of triple and month.

Coefficients for this VE system are shown in Appendix Table 10. Footnotes to the table describe how values were sampled for each draw (then taken into the 100 iterations of each scenario in the ABM). Note we assumed that waning (on the log odds scale) was the same for any and symptomatic infection, and the same for hospitalisation, ICU and death. We also assumed that peak effectiveness and waning for a third dose vaccine applied also to any subsequent vaccine doses.^{30,31} As of 1 April 2022, Omicron BA.2 was assumed to be responsible for all SARS-CoV-2 infections in Victoria – estimates of VE against BA.1 appear to continue to apply for BA.2 and as such VE was not adjusted in response to BA.2 emergence.^{28,32,33} See Appendix Figure 4 for an example of VE estimates against the Omicron variant for <60-year-olds by month following second and third vaccine doses, and Appendix Figure 5 for an example of VE estimates against hospitalisation due to the Omicron variant by month since vaccination for double and triple doses in three age strata.

Coefficients	Central	SD	Odds (%)	95% UI odds
Intercept ⁺	0.75	0.12	2.27 (68.0%)	1.67 to 2.70
			OR	95% UI
Age ≥70 years [£]	-0.26	0.12	0.77	0.61 to 0.98
Age 60-69 years [‡]	-0.13	0.061	0.88	0.78 to 0.99
Age <60 years (ref)	0	N/A	N/A	N/A

Appendix Table 10: Vaccine effectiveness log odds equation coefficients for the Omicron variant

Severity_Any [‡]	-0.78	0.27	0.46	0.27 to 0.77	
Severity_Sympt (ref)	0	N/A	N/A	N/A	
Severity_Hosp ⁺	1.13	0.26	3.11	1.87 to 5.16	
Severity_ICU [‡]	1.87	0.37	6.47	13.14 to 13.40	
Severity_Death [‡]	2.60	0.37	13.46	6.52 to 27.80	
≥3Doses [†]	0.092	0.14	1.10	0.83 to 1.45	
2 Doses (ref)	0	N/A	N/A	N/A	
Month (continuous, centered on	-0.64	0.029	0.53	0 50 to 0 56	
0.5 months after last dose) ⁺	0.04	0.025	0.55	0.50 10 0.50	
Months*Severity_Any	0	N/A	N/A	N/A	
Months*Severity_Sympt (ref)	0	N/A	N/A	N/A	
Months*Severity_Hosp ⁺	0.22	0.095	1.24	1.03 to 1.50	
Months*Severity_ICU	0.22	0.095	1.24	1.03 to 1.50	
Months*Severity_Death	0.22	0.095	1.24	1.03 to 1.50	
Months*≥3Doses [†]	0.21	0.033	1.23	1.16 to 1.32	

⁺Drawn from covariance matrix accompanying regression model on UKHSA data.⁵

[‡]Correlated 1.0 with the value in this domain drawn from covariance matrix accompanying regression model on UKHSA data.⁵ E.g., if the value drawn for Severity_Hosp was at the 63%ile of its distribution, then all other values for Severity_Any,

Severity_ICU and Severity_Death are allocated the 63% ile of their distribution.

^{*E*}The value for age was drawn independently but correlated 1.0 for \geq 70 years and 60-69 years.



Appendix Figure 4: Estimated vaccine effectiveness against the Omicron variant by month following a second and third vaccine dose, age <60 years



Appendix Figure 5: Estimated vaccine effectiveness against hospitalisation due to the Omicron variant by month since vaccination for double and triple dose in three age strata

3.2 Protection from reinfection

Current evidence suggests that previous natural infection provides considerable protection against reinfection with SARS-CoV-2.^{34,35} For the purposes of our model, we extracted protection from reinfection at approximately 6 months post-infection from a large population-level observational study conducted in Denmark in 2020³⁶ which was comparable to estimates from other studies (e.g. ³⁷⁻⁴¹). Given these estimates were derived from the first and second large outbreaks of COVID-19 in Denmark, prior to the widespread emergence of SARS-CoV-2 variants of concern, we assumed they therefore approximated the protection against reinfection with the *same* variant as the initial infection (for example, reinfection with the Omicron variant following a primary Omicron infection). This study reported estimates by age, which we recalculated by the three age groups used in our model. Note protection from natural infection by age varies more than for VE (Appendix Table 11).

For seasonal coronaviruses that cause upper respiratory tract infections in humans, infection-derived protective immunity wanes allowing for reinfection within approximately 12 months.⁴² Studies specifically investigating the duration of protection following infection with SARS-CoV-2 are relatively scarce. In the aforementioned Danish study of the protection afforded by natural SARS-CoV-2 infection,³⁶ no evidence of a decrease in immunity between 3-6 months and \geq 7 months post-infection was detected. Similarly, a total population cohort study from Sweden reported high and stable levels of protection against infections and hospitalisation over time following primary infection.³⁵ However, more recent data from Israel^{43,44} reports increasing adjusted rates of infection over time for those previously infected, from 10.5 infections per 100,000 days at risk at 4-6 months post-infection to 30.2 infections per 100,000 days at risk by \geq 12 months. In addition, recent data from the UK provides further evidence for the existence of waning of natural immunity.⁴⁵ Among unvaccinated individuals, adjusted protection against reinfection up to 1 year following primary infection was 86%; this fell to 69% >1 year after primary infection.

Therefore, we modelled immunity and waning following natural infection by assuming an OR for waning per month of 0.825 (halfway between the waning of immunity for symptomatic infection following the third dose of a vaccine and no waning in the VE waning system described above). This approximates the relative change in natural protection as reported in the aforementioned Israeli study between 4 and 12 months following primary infection.⁴⁴ This parameter is genuinely very uncertain, so we specified a SD of 40% of its value on the log odds scale, giving a 95% uncertainty interval for the OR of monthly waning of 0.71 to 0.96 (much wider in relative terms than that for waning VE). Estimates for protection against reinfection (i.e., any infection) were then adjusted proportionally based on the VE system outlined above to also obtain reinfection protection estimates for symptomatic infection, hospitalisation, ICU admission, and death (Appendix Table 11). Note these apply to unvaccinated individuals and are further adjusted as described below for vaccinated individuals. See Appendix Figure 6 for an example of reinfection protection estimates following primary infection for <60-year-olds, and Appendix Figure 7 for the same estimates among ≥70-year-olds.

25

Coefficients	Central	SD	Odds (%)	95% UI odds
Intercept	2.56	0.25 ⁺	12.94 (92.8%)	(7.92 to 21.12)
			OR	95% UI
Age ≥70 years [‡]	-1.62	0.45 ⁺	0.20	(0.08 to 0.48)
Age 60-69 years [‡]	-0.55	0.25 ⁺	0.58	(0.35 to 0.94)
Age <60 years (ref)	0	N/A	N/A	N/A
Severity_Any (ref)	0	N/A	N/A	N/A
Severity_Sympt [‡]	0.78	0.30	2.18	(1.21 to 3.93)
Severity_Hosp [‡]	1.91	0.26	6.75	(4.06 to 11.24)
Severity_ICU [‡]	2.65	0.37	14.15	(6.85 to 29.23)
Severity_Death [‡]	3.38	0.37	29.37	(14.22 to 60.65)
Month (continuous) [^]	-0.192	0.077	0.83	(0.71 to 0.96)

Appendix Table 11: Natural protection log odds equation coefficients for reinfection with the same variant as the primary infection

[†]SD approximated from CI about VE in ³⁶.

[‡]Correlated 1.0 with other values drawn in this domain.

[^]This coefficient was fixed at half the waning of triple and more doses of vaccine. The uncertainty is high here, so we simply set the SD at 40% of the central estimate.

Appendix Figure 6: Estimated protection against any reinfection by month since primary infection, age <60 years, unvaccinated





Appendix Figure 7: Estimated protection against any reinfection by month since primary infection, age ≥70 years, unvaccinated

3.3 Hybrid immunity

Immunity provided by the combination of vaccination and natural infection (hybrid immunity) has been quantified by, for example, studies conducted in Israel^{46,47} a large population-level study in Sweden,³⁵ and a study in Qatar.³³ In both Israeli studies, protection against reinfection was assessed among previously infected individuals either receiving a single dose of the BNT162b2 mRNA vaccine or remaining unvaccinated, and the hazard ratio for reinfection among individuals both infected and subsequently vaccinated was 0.18 compared to those previously infected and unvaccinated. In the study from Sweden, hybrid immunity was found to provide additional protection above natural immunity for both reinfection and hospitalisation risk,³⁵ while the study from Qatar also demonstrated that hybrid immunity provides greater protection than vaccination or natural infection alone.³³ The kinetics of

hybrid immunity are complex however, owing to variability in terms of timing of infection and vaccination (and the time elapsed between these two sensitizing events) in addition to consideration of dominant circulating variants, for example, and several potential sources of bias in estimates.³⁵ Current evidence suggests that the two types of immunity may act independently to confer an overall combined level of protection;³³ accordingly we calculated protection for an individual agent at any given point in time as $1 - (1 - VE) \times (1 - protection from prior infection)$.

3.4 The effect of immunity on onward transmission

Data quantifying the effect of immunity (either from vaccination or previous infection) on ongoing transmission if one becomes infected is scarce. Guided by evidence of reduced transmission for Omicron following vaccination in Danish households⁴⁸ and evidence that this reduced transmission does wane over time⁴⁹ we assumed that the reduction in ability to transmit the virus if infected following vaccination or previous infection follows the same function as VE and/or natural protection against any infection (and wanes accordingly).

4 MORBIDITY AND MORTALITY ESTIMATES

4.1 Acute COVID-19 morbidity

We estimated the number of asymptomatic, non-hospitalised symptomatic, hospitalised symptomatic, and ICU-admitted cases for the quantification of acute COVID-19 morbidity, and deaths for the quantification of HALYs lost due to death from COVID-19. We measured morbidity impacts using disability rates (DR), according to the severity of acute infection (cases managed in the community, being either mild or moderate, and cases requiring hospitalisation, either managed in ward only or additionally including ICU admission) using estimates from the Global Burden of Disease (GBD) study.⁵⁰ For ICU admissions, the DR was based on the GBD disability weight (DW) for 'severe chronic obstructive pulmonary disease (COPD) and other respiratory infections', to reflect acute respiratory distress syndrome (ARDS). The GBD does not have an estimate for ARDS directly – the estimate used here is the GBD's most severe rating for respiratory infections.⁵⁰ We assumed that survivors return to their baseline health status (DR = 0) following a specified recovery period as described below. This does not apply to those who go on to develop symptoms of long COVID – morbidity associated with long COVID was quantified separately.

Estimates are presented separately for high virulence variant infections (using data relating to the Delta variant), and low virulence variant infections (using data relating to the Omicron variant). The duration of symptoms for the purpose of morbidity calculations changes for low virulence variant infections compared to a high virulence variant, however the DRs applied are the same for both. The duration of symptoms for low virulence variants and high virulence variants was obtained from a large ongoing UK-based study, comparing acute illness parameters for Omicron vs. Delta infections.⁵¹ In this study, the duration of symptomatic infection was not stratified by hospitalisation status – as such, estimates relating to cases managed in the community are for those with infection of duration 21 days or less.⁵¹ For duration of symptoms for hospitalised patient sub-groups, the length of stay defined in Appendix Table 7 are applied (including either hospital stay only, or hospital stay and ICU stay).

Morbidity loss for the four categories of symptomatic SARS-CoV-2 infection with a high virulence variant (Appendix Table 12) was calculated as follows:

- Morbidity for symptomatic, but not hospitalised, infections were split evenly as 50% moderate infection, with a DR of 0.051 (95% Cl 0.032-0.074), and 50% mild infection, with a DR of 0.006 (95% Cl 0.002-0.012), both with a mean duration of 8.89 days (95% Cl 8.61-9.17).⁵¹
- Morbidity for hospitalised patients not requiring ICU admission assumes a period of 1 week prior to hospitalisation with moderate acute infection, with a DR of 0.051 (95% CI 0.032-0.074), followed by a duration of hospital stay varying by age (as per Appendix Table 7), all with a DR of 0.133 (95% CI 0.088-0.190) for severe acute infection. A duration of 1-week post-hospitalisation for return to baseline health was applied, with a DR reducing linearly to zero from the severe acute infection DR.
- Morbidity for hospitalised patients requiring ICU admission assumes a period of 1 week prior to hospitalisation with moderate acute infection, with a DR of 0.051 (95% CI 0.032-0.074), followed by a duration of stay in hospital (on a general ward) varying by age (as per Appendix Table 7), all with a DR of 0.133 (95% CI 0.088-0.190) for severe acute infection. This is followed by duration of stay in ICU as per Appendix Table , all with a DR of 0.408 (95% CI 0.273-0.556) to approximate ARDS. A duration of 2 weeks for return to baseline health was applied, with a DR reducing linearly to zero from the ARDS DR.

Morbidity loss for the four categories of symptomatic SARS-CoV-2 infection by a low-virulence variant (Appendix Table 13) was calculated as follows:

- The proportion of mild/moderate symptomatic, but not-hospitalised, infections were altered compared to high-virulence variant infections: 28% have moderate infection, with a DR of 0.051 (95% CI 0.032-0.074), and 72% have mild infection, with a DR of 0.006 (95% CI 0.002-0.012), both with duration of 6.87 days (95% CI 6.58-7.16). The proportion with mild vs. moderate severity of infection was estimated from the aforementioned UK-based study, which found the odds of 'classic' acute COVID-19 symptoms were reduced by 44% for Omicron compared to Delta infections.⁵¹
- Morbidity for hospitalised patients not requiring ICU assumes a period of 1 week prior to hospitalisation with moderate acute infection, applying a DR of 0.051 (95% CI 0.032-0.074), followed by a duration of stay varying by age as per Appendix Table 7, all with DR of 0.133 (95% CI 0.088-0.190) for severe acute infection. A duration of 1-week post-hospitalisation for return to baseline health was applied, with a DR reducing linearly to zero from the severe acute infection DW.
- Morbidity for hospitalised patients requiring ICU admission assumes a period of 1 week prior to hospitalisation with moderate acute infection, with a DR of 0.051 (95% CI 0.032-0.074), followed by a duration of stay in hospital (on a general ward) varying by age as per Appendix Table 7, all with DR of 0.133 (95% CI 0.088-0.190) for severe acute infection. This is followed by duration of stay in ICU as per Appendix Table 7, all with DR of 0.408 (95% CI 0.273-0.556). A duration of 2 weeks for a post-hospitalisation for return to baseline health was applied, with the DW reducing linearly to zero from the ARDS DR.

The overall morbidity for each clinical infection category was calculated as the sum of the symptom severity-specific DR multiplied by the symptom duration (in years). Note these are not additive.

Category	Symptom severity (health state)	Duration in days, mean (95% Cl)	Disability Rate [†] , mean (95% Cl)
	Moderate acute infection	7	0.051 (0.032-0.074)
Admitted to ICU	Severe acute infection (ward)	Appendix Table 7	0.133 (0.088–0.190)
	In-ICU (COPD for ARDS)	Appendix Table 7	0.408 (0.273-0.556)
	Return to baseline health	14	Linearly to 0 from ARDS DR
	Moderate acute infection	7	0.051 (0.032-0.074)

Appendix Table 12: Disability rate distribution and duration by SARS-CoV-2 category, high virulence variant

Admitted to hospital, no ICU	Severe acute infection (ward)	Appendix Table 7	0.133 (0.088–0.190)
	Return to baseline health	7	Linearly to 0 from severe acute infection DW
Symptomatic, not	50% Moderate acute infection	8.89 (8.61-9.17)	0.051 (0.032-0.074)
admitted	50% Mild acute infection	8.89 (8.61-9.17)	0.006 (0.002–0.012)

[†]Disability rate applied based on DWs for equivalent health states from ⁵⁰

Appendix Table 13: Disability rate distribution and duration by SARS-CoV-2 category, low virulence variant

Category	Symptom severity (health state)	Duration in days, mean (95% CI)	Disability Rate [†] , mean (95% Cl)
Admitted to ICU	Moderate acute infection	7	0.051 (0.032-0.074)
	Severe acute infection (ward)	Appendix Table 7	0.133 (0.088–0.190)
	In-ICU (COPD for ARDS)	Appendix Table 7	0.408 (0.273-0.556)
	Return to baseline health	14	Linearly to 0 from ARDS DW
Admitted to hospital, no ICU	Moderate acute infection	7	0.051 (0.032-0.074)
	Severe acute infection (ward)	Appendix Table 7	0.133 (0.088–0.190)
	Return to baseline health	7	Linearly to 0 from severe acute infection DW
Symptomatic, not admitted	28% Moderate acute infection	6.87 (6.58-7.16)	0.051 (0.032-0.074)
	72% Mild acute infection	6.87 (6.58-7.16)	0.006 (0.002–0.012)

[†]Disability rate applied based on DWs for equivalent health states from ⁵⁰

Given the above, the following HALY loss was applied to each agent based on their clinical outcome category (given the SDs of the inputs approximate 20% of their means, we included uncertainty here by applying a multiplier of 1 with SD 0.2 to acute HALYs generated by the model):

- Current Omicron and low-virulence new variant:
 - For an infected, asymptomatic agent: 0
 - For an infected, symptomatic agent: 0.000350087671
 - For a hospitalised agent: 0.000978082 + ((length of hospital stay in days/365)*0.133) + 0.001275342
 - For an ICU admitted agent: 0.000978082 + ((length of hospital stay in days/365)*0.133)
 + ((length of ICU stay in days/365)*0.408) + 0.007824658
- High-virulence new variant:
 - For an infected, asymptomatic agent: 0
 - For an infected, symptomatic agent: 0.000694150685

- For a hospitalised agent: 0.000978082 + ((length of hospital stay in days/365)*0.133) + 0.001275342
- For an ICU admitted agent: 0.000978082 + ((length of hospital stay in days/365)*0.133)
 + ((length of ICU stay in days/365)*0.408) + 0.007824658

4.2 Long COVID morbidity

Ongoing symptoms following acute SARS-CoV-2 infection can be grouped into two phases: the 'acute post-COVID symptoms' or 'ongoing symptomatic' phase (up to 12 weeks post-infection) and 'long COVID' phase (≥12 weeks post-infection).^{52,53} Long COVID, formally termed 'Post-Acute Sequelae of SARS-CoV-2' and defined in ICD-10 classification as 'Post-COVID-19 Condition', describes the persistence and/or emergence of a heterogeneous group of physical and cognitive symptoms following acute SARS-CoV-2 infection.^{53,54} The exact mechanisms and symptom profile of long COVID are yet to be fully understood. Comparisons have been made with chronic fatigue syndrome, as fatigue, muscle weakness, and concentration difficulty (or 'brain fog') have been some of the most reported symptoms.^{55,56} However, other notable symptoms unique to long COVID include an impaired sense of taste (dysgeusia)/smell (dysosmia) and shortness of breath (dyspnoea).⁵⁷

For the purposes of this model a bottom-up approach was utilized to estimate long COVID morbidity, calculating a morbidity estimate individually for each major long COVID symptom as the product of its disability rate, duration and prevalence among acute COVID-19 survivors. The disability rate for each symptom has been estimated from the GBD study DWs.⁵⁰ Some long COVID symptoms do not have direct health states for which DWs exist – in these cases best estimates have been determined from related health states. For example, the DWs of other sensory conditions (mild hearing loss and mild visual impairment) have been used as proxies for the DWs of dysosmia and dysgeusia (the full list of DWs applied are presented in Appendix Table 15).

Symptom prevalence estimates were drawn from risk differences between COVID-19 cases and COVIDnegative controls from large international studies. Four variables were identified from the available literature with which to stratify long COVID estimates: age (adult vs. child), severity of acute infection (approximated for this model as hospitalised vs. community-managed cases), vaccination (at least 2 doses vs. less than 2, with waning not considered), and SARS-CoV-2 variant (high vs. low virulence variant). The 'base cases' for which prevalence estimates were available in the literature are adults/children infected with a pre-Omicron variant of SARS-CoV-2 (i.e. 'high virulence' group), who are not vaccinated at the time of infection.

Symptom prevalence was drawn from four studies:

- A case-control study by Vedel Sørensen et al. conducted in Denmark: used to obtain prevalence of physical long COVID symptoms, for adult patients diagnosed with acute COVID-19 6-12 months previously, compared to PCR-negative/seronegative controls, separately for individuals hospitalised vs. non-hospitalised during the acute disease period.⁵⁸
- A case-control study by Caspersen et al. based in Norway: used to obtain prevalence of cognitive long COVID symptoms for adult patients either 1 to 6 or 11 to 12 months post-infection. Patients were stratified into 'mild' vs. 'moderate/severe' cases, with moderate cases including those not hospitalised weighting was therefore applied to the prevalence estimates for these groups to achieve the risk ratio (RR) for any long COVID symptoms between hospitalised and non-hospitalised patients found by Vedel Sørensen et al. (RR=2) and approximate the prevalence of symptoms for previously hospitalised vs. non-hospitalised groups.^{58,59}
- A multi-country case-control study by Magnúsdóttir et al.: used to obtain the prevalence of psychological long COVID symptoms (insomnia, anxiety and depression), stratified by hospitalised vs. community adult cases. Insomnia occurred at a greater prevalence for cases compared to controls for hospitalised and non-hospitalised groups, however, anxiety and depression only occurred more frequently in hospitalised cases compared to controls (not for community cases vs. controls).⁶⁰
- A systematic review by Behnood et al.: used to obtain prevalence estimates for children (age 0-17), for whom there is estimated to be a much lower risk of ongoing symptoms.⁶¹ The metaanalysis from this review combined data from 5 large, controlled studies undertaken in children. Sub-groups by hospitalisation/severity are not considered for children, given the lower risk of hospitalisation compared to adults.

Base case prevalence estimates were then adjusted to account for vaccination, and low virulence variants of SARS-CoV-2. The prevalence of each symptom is multiplied by an OR of 0.55 for those who were vaccinated (both adults and children), given findings from large population-based studies by Antonelli et. al. and the Office for National Statistics in the UK, indicating reduced odds of long COVID symptoms for those vaccinated, compared to those unvaccinated.^{62,63} Separately, the prevalence of each

symptom was multiplied by an OR of 0.25, based on findings from a recent UK-based case-control study showing a reduced odds of any ongoing symptoms at least 4 weeks post-infection for Omicron variant infections compared to Delta variant infections.⁶⁴ It is assumed that this reduced symptom prevalence will continue into the long COVID period at least 12 weeks post infection.

A multivariate method was applied to account for the joint probability of having two long COVID symptoms, by multiplying the prevalence of each combination of two symptoms, then using multiplicative adjustment to combine DWs for such comorbidity.⁶⁵ The probability of having three or more symptoms was assumed to be low, and therefore only the joint probability of two symptoms was included. The following formulae were used for multiplicative adjustment:

Combined prevalence = $Frequency_{Symptom A} \times Frequency_{Symptom B}$

Combined $DW = 1 - (1 - DW_{Symptom A}) \times (1 - DW_{Symptom B})$

The duration of each symptom was estimated based on a recent analysis by Wulf Hanson et. al., which found a median duration of long COVID symptoms across 10 cohort studies of 3.99 months (interquartile range [IQR] 3.84-4.20) for community cases, and 8.84 months (IQR 8.10-9.78) for previously hospitalised cases.⁶⁶ For community cases, a linear decline in the DW applied at onset to full health at 8 months (DR = 0) was applied. For previously hospitalised cases, the given DW was applied to 6 months post infection, followed by a linear decline to 12 months (DR = 0). Exceptions to this were psychological symptoms, for which a shorter duration has been documented – for these symptoms, a linear decline in the DW from onset to 6 months post-infection was applied for both sub-groups.⁶⁰ Additionally, as symptoms in children resolve in a much shorter time frame compared to adults, a time frame of 3 months post-infection was applied for long COVID symptoms in children, followed by immediate return to full health (DR = 0).^{67,68} Each time frame applied excludes the duration of acute infection, but includes the ongoing symptomatic phase in addition to the long COVID period.⁵² No difference in duration is applied for low vs. high virulence variants, given the lack of data available to inform this. Duration and prevalence estimates for each symptom, across relevant patient sub-groups, are shown in Appendix Table 14.

Symptom	Prevalence ⁺		Duration
Adult community c	ases		
	High virulence	Low virulence	
Dysosmia	10.4%	2.6%	Linear decline from onset (1-week post-infection) to 8 months
Dysgeusia	8.2%	2.1%	Linear decline from onset (1-week post-infection) to 8 months
Fatigue	7.8%	2.0%	Linear decline from onset (1-week post-infection) to 8 months
Dyspnoea	4.2%	1.1%	Linear decline from onset (1-week post-infection) to 8 months
Chest pain	1.8%	0.5%	Linear decline from onset (1-week post-infection) to 8 months
Muscle weakness	4.1%	1.0%	Linear decline from onset (1-week post-infection) to 8 months
Dizziness	2.3%	0.6%	Linear decline from onset (1-week post-infection) to 8 months
Muscle/joint pain	3.2%	0.8%	Linear decline from onset (1-week post-infection) to 8 months
Headache	3.0%	0.8%	Linear decline from onset (1-week post-infection) to 8 months
Numb limbs	3.2%	0.8%	Linear decline from onset (1-week post-infection) to 8 months
Concentration difficulty [*]	7.6%	1.9%	Linear decline from onset (1-week post-infection) to 8 months
Memory impairment*	5.5%	1.4%	Linear decline from onset (1-week post-infection) to 8 months
Insomnia	5.3%	1.3%	Linear decline from onset (1-week post-infection) to 8 months
Adult hospitalised	cases#		
Dysosmia	7.0%		6 months from onset (4 weeks post-infection), followed by linear decline to 12 months
Dysgeusia	6.9%		6 months from onset (4 weeks post-infection), followed by linear decline to 12 months
Fatigue	13.1%		6 months from onset (4 weeks post-infection), followed by linear decline to 12 months
Dyspnoea	10.3%		6 months from onset (4 weeks post-infection), followed by linear decline to 12 months
Chest pain	4.1%		6 months from onset (4 weeks post-infection), followed by linear decline to 12 months
Muscle weakness	11.3%		6 months from onset (4 weeks post-infection), followed by linear decline to 12 months

Appendix Table 14: Long COVID symptom prevalence and duration estimates

Dizzinoss	1.8%		6 months from onset (4 weeks post-infection), followed	
Dizziness	4.070		by linear decline to 12 months	
Muscle/inint nain	6.2%		6 months from onset (4 weeks post-infection), followed	
	0.370		by linear decline to 12 months	
Headache	1 3%		6 months from onset (4 weeks post-infection), followed	
neadache	4.370		by linear decline to 12 months	
Numh limhs	7.0%		6 months from onset (4 weeks post-infection), followed	
	7.078		by linear decline to 12 months	
Concentration	10.9%		6 months from onset (4 weeks post-infection), followed	
difficulty*	10.576		by linear decline to 12 months	
Memory	1/1 2%		6 months from onset (4 weeks post-infection), followed	
impairment*	14.370		by linear decline to 12 months	
Incompia	10 /%		Linear decline from onset (4-weeks post-infection) to 6	
Insomma	19.4%		months	
Anviety	11.8%		Linear decline from onset (4-weeks post-infection) to 6	
Analety			months	
Depression	22.2%		Linear decline from onset (4-weeks post-infection) to 6	
Depression	23.270		months	
Children				
	High	Low		
	virulence	virulence		
Dysosmia	8.0%	2.0%	3 months from onset (1-week post-infection)	
Headache	5.0%	1.3%	3 months from onset (1-week post-infection)	
Eye soreness	2.0%	0.5%	3 months from onset (1-week post-infection)	
Sore throat	2.0%	0.5%	3 months from onset (1-week post-infection)	
Cognitive difficulties	3.0% 0.8%		3 months from onset (1-week post-infection)	

Prevalence estimates presented are for unvaccinated sub-groups – each estimate is multiplied by OR = 0.55 to achieve prevalence for vaccinated groups.

⁺*Prevalence measured as a risk difference between cases and controls.*

*Community and hospitalised sub-group prevalence estimates achieved through weighting of estimates for mild and severe subgroups from ⁵⁹

*No difference in prevalence applied for low vs. high virulence variant infections, for the hospitalised patient sub-group.

Appendix Table 15: Long COVID symptom disability weight estimates

Symptom	Disability Rate ⁺ (95%	Health state and justification
-,	CI)	
Adults		
Dysosmia	0.01 (0.004-0.020)	Health state: hearing loss, mild & presbyopia.
		Assumed to be equivalent to mild impairment of other
		senses.
Dysgeusia	0.01 (0.004-0.020)	Health state: hearing loss, mild & presbyopia
		Assumed to be equivalent to mild impairment of other
		senses.
Fatigue	0.051 (0.036-0.062)*	Health state: infectious disease, post-acute consequences
		(adjusted down for depression and pain).

Cognitive difficulty	0.045 (0.028-0.066)	Health state: attention deficit hyperactivity disorder	
		(ADHD).	
		ADHD is characterised by difficulty with concentration and	
		memory.	

[†]Disability Rate applied based on DWs for health states from ⁵⁰

*DW not directly taken from GBD study. Weight and 95% CI estimated by adjusting existing weights.

Overall long COVID morbidity estimates were calculated for each sub-group, by adding the morbidity contributions for each individual symptom and joint symptom combinations. These are presented in Appendix Table 16. They are applied to the ABM output for the relevant group of symptomatic acute COVID-19 survivors – asymptomatic infections are excluded. Uncertainty is assumed to be high; therefore, a SD of +/- 30% is applied to each estimate.

Appendix Table 16: Long COVID morbidity estimates

Population group		Unvaccinated (95% UI)	Vaccinated (95% UI)
High virulence variant, symptomatic			
Adults	Non-hospitalised	0.0075 (0.0031-0.0119)	0.0038 (0.0016-0.0060)
Addits	Hospitalised	0.0442 (0.0182-0.0701)	0.0186 (0.0077-0.0296)
Children*		0.0010 (0.0004-0.0016)	0.0006 (0.0002-0.0009)
Low virulence variant, symptomatic			
Adulta	Non-hospitalised	0.0017 (0.0007-0.0026)	0.0009 (0.0004-0.0014)
Adults	Hospitalised	0.0442 (0.0182-0.0701)	0.0186 (0.0077-0.0296)
Children*		0.0003 (0.0001-0.0004)	0.0001 (0.00006-0.0002)

95% UI produced using +/-30% standard deviation.

OR of 0.25 applied to prevalence estimates from high-virulence variant cases to approximate prevalence of long COVID symptoms among low virulence variant cases. OR of 0.55 applied to prevalence estimates from unvaccinated (<2 doses) cases to approximate prevalence of long COVID symptoms among vaccinated cases.

*Parameterised as \leq 18 years in the model.

4.3 Longer term consequences of SARS-CoV-2 infection

In addition to the long COVID symptoms described above, SARS-CoV-2 infection has been associated with an increased risk of cardiovascular outcomes including myocarditis, stroke, arrhythmias, and acute coronary disease, as well as other sequelae including Type 2 Diabetes Mellitus and acute kidney injury. This risk has been identified particularly in those hospitalised during their acute infection.⁶⁹ It is currently unknown whether the risk of chronic outcomes will reduce over time as is assumed for the above discussed long COVID symptoms, or whether such damage confers a lifetime increase in risk. Therefore, this risk has not been included in this model.

4.4 Mortality

For each COVID-19 death during the 18-month intervention duration, we estimate their future HALY loss (3% discount rate) as follows:

- All-cause mortality rates by sex and age for Australia for 2019 were sourced from the Global Health Data Exchange (GHDx). An ongoing 2% per annum fall in mortality rates (uniform by sex and age) was assumed. On average, people dying of COVID-19 have more comorbidities and are frailer than people not dying of COVID-19. Therefore, we assumed the counterfactual future allcause mortality rates for people dying of COVID-19 (had they not died of COVID-19) would have been twice that of the general population. Given this is uncertain, we assumed a 10% SD about the 2.0 rate ratio (i.e., 95% UI 1.64 to 2.43).
- All-cause morbidity rates by sex and age were calculated as the GHDx 2019 YLDs for each sex by age group, divided by the population size in 2019, to generate a proportion of quality of life lost (also called prevalent YLDs, or pYLDs). These were assumed constant into the future by sex and age as all-cause morbidity rates by sex and age have been stable over time in the GBD.⁵⁰ Just as people who die of COVID-19 have higher counterfactual mortality rates into the future if they had not died (above), the same applies for morbidity. We used our experience with the New Zealand Burden of Disease study⁷⁰ that separately estimates Maori and non-Maori morbidity, where for an all-cause mortality rate ratio of two the all-cause morbidity ratio is approximately 1.5. Accordingly, we assumed the pYLD rate for those dying of COVID-19 into the future (had they counterfactually not died) would have been 1.5 times higher (95% UI 1.23 to 1.82).

The ABM has agents stratified by ten-year age group. Accordingly, we estimated the future HALY loss for decedents aged 5, 15, ..., 95 and 105 years old. Estimates are shown in Appendix Table 17, with standard deviations across Monte Carlo simulated values using the above uncertainties. The model does not distinguish sexes, so we generated an average HALY loss by age, each with uncertainty expressed as SD as a percentage of the HALY loss estimate. Total HALY loss for each COVID-19 policy scenario was the sum of acute COVID-19 morbidity, long COVID-19 morbidity, and future HALY losses from COVID-19 deaths.

Appendix Table 18 shows HALYs by age (with same % SD for uncertainty as in Appendix Table 17) for HALYs alternatively discounted at 1.5% (following UK Treasury recommendations⁷¹ of health gains discounted at 1.5% and costs at 3.5%, used as part of sensitivity analyses).

	Females		Males			Combined (average males & females)		
Age group	Average HALY loss	SD HALY loss	SD as % of Average	Average HALY loss	SD HALY loss	SD as % of Average	Average HALY loss	Average SD as % of HALY loss
0-9 yrs	23.94	0.55	2.40%	24.28	0.48	2.00%	24.11	2.20%
10-19 yrs	21.89	0.65	3.00%	22.23	0.56	2.50%	22.06	2.75%
20-29 yrs	19.86	0.7	3.60%	20.06	0.6	3.00%	19.96	3.30%
30-39 yrs	17.7	0.7	4.00%	17.62	0.61	3.50%	17.66	3.75%
40-49 yrs	15.04	0.68	4.60%	14.6	0.61	4.10%	14.82	4.35%
50-59 yrs	11.82	0.64	5.50%	11	0.57	5.20%	11.41	5.35%
60-69 yrs	8.17	0.56	6.80%	7.2	0.5	6.90%	7.685	6.85%
70-79 yrs	4.54	0.41	9.10%	3.82	0.36	9.40%	4.18	9.25%
80-89 yrs	1.78	0.23	13.10%	1.52	0.2	13.00%	1.65	13.05%
90-99 yrs	0.48	0.1	20.90%	0.5	0.09	18.20%	0.49	19.55%

Appendix Table 17: HALY losses (3% discount rate) for each COVID death, by sex and age

100% correlation on uncertainty between age groups

Appendix Table 18: HALY losses (1.5% discount rate) for each COVID death, by sex and age

	Females	Males	Combined (average males & females)
Age	Average	Average	Average
group	HALY loss	HALY loss	HALY loss
0-9 yrs	36.40	36.66	36.53
10-19 yrs	32.38	32.49	32.43
20-29 yrs	28.28	28.12	28.20
30-39 yrs	24.06	23.56	23.81
40-49 yrs	19.43	18.55	18.99
50-59 yrs	14.49	13.27	13.88
60-69 yrs	9.48	8.27	8.88
70-79 yrs	5.01	4.19	4.60
80-89 yrs	1.87	1.60	1.74
90-99 yrs	0.48	0.51	0.50

5 ECONOMIC ANALYSES

5.1 Testing costs

In Victoria currently, approximately one third of cases are detected with PCR and two thirds detected with rapid antigen testing (RAT).⁷² We included costs for PCR tests based on a reported PCR test positivity rate of approximately 20%.⁷³ Given we assume 50% case ascertainment (i.e., the number of infections output in our model is double the number of cases that would likely be notified in Victoria) we applied a cost of 0.83 PCR tests (0.5*0.33*5) to each infection. The current RAT positivity rate in Victoria is unknown, given only positive RAT results are reported. As such we assumed a 10% RAT positivity rate (given extensive use of RATs following, for example, exposure to a confirmed case in Victoria) and applied the cost of 3.33 RAT kits (0.5*0.66*10) to each infection. Unit costs for PCR and RAT testing were estimated at \$42.50 (MBS item 69479)⁷⁴ with +/- 10% uncertainty applied and \$7.60 (median wholesale price as reported by the Australian Competition and Consumer Commission⁷⁵, with +/- 10% uncertainty applied) respectively.

5.2 Acute COVID-19 morbidity expenditure

We estimated acute COVID-19-related health expenditure using an ingredients approach. For each clinical patient subgroup, we estimated the expected patient pathway through the health system and calculated total health expenditure by first estimating resource use required for a typical patient (e.g., hospital or outpatient visits, or drugs) and then multiplying by unit costs for each of the specified resources based on model outputs. For ICU-admitted patients, we added the cost of their ICU stay onto the cost of a hospital stay.

Appendix Table 19 shows resource use assumptions. The SARS-CoV-2 pandemic is expected to add additional costs to hospital operations, adjusting for complexity of patients and added infection control requirements including the need for isolation of patients, fitting of personal protective equipment, and enhanced cleaning regimens. As a result, inpatient and ICU hospital costs have been scaled up by 20% to account for these additional costs.

Patient Subgroup	Resource	Explanation
		Assume all patients will have 2 GP consultations (in
	GP visit	addition to those applied for non-ICU hospitalisation), for
Treated in ICU (note		example as part of post-discharge follow-up
for these patients, resources from a non-	ER visit	Captured in non-ICU hospitalisation, no additional cost applied
ICU hospitalisation stay are also added)	ICU	Daily cost of ICU admission multiplied by length of ICU stay (see Appendix Table 7)
	Inpatient (non-ICU)	Added as per costs for non-ICU hospitalisation below
	Pandemic loading	All hospital costs have 20% loading for pandemic
	CD visit	Assume all patients will have 2 GP consultations prior to
		hospital admission
	ER visit	Base fee charged for presenting to an ER
	Innatient	Cost of inpatient day multiplied by length of stay (see
Hospitalised	inpatient	Appendix Table 7)
	Pandemic loading	All hospital costs have 20% pandemic loading
		Approximately 10% of hospitalised patients are
	Readmission	readmitted. ⁷⁶ As such, hospitalisation costs are multiplied
		by 1.1.
	CD Vicit	Assume half of all patients attend a GP appointment
Comparison and in	GP VISIL	during their illness
Symptomatic	Daracotamol	Assume all patients will purchase 1 packet of paracetamol
	FaidlelaiiiUi	for symptomatic treatment
Asymptomatic	No resources	N/A

Appendix Table 19: Resource use assumptions by SARS-CoV-2 category

ER: emergency room, ICU: intensive care unit, LOS: length of stay, GP: general practitioner

Unit costs for each resource are shown in Appendix Table 20.

Appendix Table 20: Unit costs for healthcare resource use

Resource	Cost (2022 AUD)	Source	Detail
Paracetamol	\$6.80	PBS item 10582Y (100 units, 500mg) ⁷⁷	For symptomatic treatment of mild illness
GP visit	\$39.10	MBS item 23 (level B general consultation) ⁷⁸	
ER visit for dyspnoea	\$907.68	Data from NHCDC Report Round 2014 (financial year 2019-20) ⁷⁹	Adjusted to 2022 cost
Inpatient day	\$1644.06	Data from H1N1 outbreak using AR-DRG code ⁸⁰	Total cost of inpatient day post ICU. Also assumed for all non-ICU patients. Adjusted to 2022 cost.
ICU day	\$6710.86	Micro-costed from H1N1 outbreak ⁸⁰	Total cost per day admitted to ICU. Allied health and overheads included. Adjusted to 2022 cost.

PBS: pharmaceutical benefits scheme, MBS: Medicare benefits schedule, AR-DRG: Australian-refined diagnostic related groups, ICU: intensive care unit. All costs have +/- 10% uncertainty on log normal distribution applied. All costs in Australian dollars Given the above, the following costs were applied for acute COVID-19-related health expenditure (note these costs are additive, unlike the morbidity calculations above):

- For an infected, asymptomatic agent: no additional costs
- For an infected, symptomatic agent: add 0.5*[GP visit cost] and 1*[paracetamol cost]
- If an agent is hospitalised (*in addition* to symptomatic agent costs):
 - Add 1.5*[GP visit cost] and 1.2*[ER visit cost]
 - Add length of hospital stay (days)*[cost of inpatient hospital bed per day]*1.1*1.2
- If an agent is admitted to ICU (in addition to hospitalised agent costs):
 - Add 2*[GP visit cost]
 - Add length of ICU stay (days)*[cost of ICU bed per day]*1.2

5.3 Long COVID morbidity expenditure

Few observational studies of long COVID occurrence, in Australia or internationally, have included thorough data collection regarding healthcare utilisation following acute COVID-19 infection. Additionally, clinical data on healthcare use relating to long COVID is not currently collected in Australia – the ICD-10 code assigned for long COVID is yet to have associated published hospital data. Therefore, in order to estimate the healthcare costs associated with long COVID, we applied expert estimates on the likely healthcare use for those experiencing long COVID symptoms, based on available international data and formal guidelines for healthcare professionals in Australia provided by the Royal Australian College for General Practitioners (RACGP) and the National COVID-19 Clinical Evidence Taskforce.^{81,82} An additional informal expert knowledge elicitation was also conducted with General Practitioners (GPs) to confer information obtained from the former sources. Appendix Table 21 shows the resources applied to each sub-group; unit costs are indicated in Appendix Table 22. For estimates specific to particular long COVID symptoms, costs are assigned to proportions of symptomatic acute COVID-19 survivors with the relevant long-COVID-19 symptom (see 'long COVID morbidity' section above for methodology).

The following treatment items are considered:

GP attendance: current guidelines indicate that long COVID is predominantly managed in the primary care setting, though few evidence-based management options currently exist.⁸¹ In a survey of COVID-19 survivors 6-months post-acute illness (pre-Omicron, unvaccinated cohort) in Zurich, Switzerland, Menges et al. found that 63% of previously hospitalised adults, and 29% adult community cases, had at least 1 GP consult related to COVID-19 following the acute illness period.⁸³

43

The estimate for hospitalised adults is multiplied by 1.5 to include GP use in the second 6 months (reflecting the estimated duration of long COVID for this sub-group).

- Specialist attendance: a survey of symptomatic COVID-19 survivors (pre-Omicron, unvaccinated cohort) attending a post-COVID assessment clinic in London found that 18% were referred on to specialist management, most commonly to a cardiologist, neurologist or ENT specialist.⁸⁴ Therefore, 18% of those who attend a GP at least once are assumed to go on to see a specialist (single consult).
- ER attendance: ER attendance is calculated specifically for those experiencing dyspnoea or chest pain these groups are assumed to present to ER once throughout the disease course.
- Medication: medication use is estimated based on RACGP guidelines and informal expert elicitation with GPs. Short-acting beta-agonists (salbutamol), or corticosteroids (budesonide), are applied for patients with ongoing dyspnoea.⁸² Paracetamol is applied for those with headache and muscle/joint pain.⁸²
- Diagnostics: routine testing is advised by RACGP to rule out other causes of symptoms, e.g., anaemia. Therefore, for those with fatigue, routine blood testing including iron studies, a full blood examination, electrolytes and thyroid function tests are costed. It is assumed that any diagnostic tests required for those with ongoing dyspnoea/chest pain (e.g., chest x-ray or ECG as per RACGP guidelines) occur at ER presentation, so are not separately included to avoid double costing. Other symptoms are judged as being too infrequent to consider any other specific testing.

Magnusson et al. conducted a large study in Norway on healthcare use in children in the period 5-12 weeks post-COVID infection.⁸⁵ No significant difference was found in healthcare utilisation between cases and COVID-negative controls during this period. This is in keeping with the relatively low morbidity impact of long COVID estimated for children compared to adults. Therefore, costs for children are not considered.

The proportions indicated in Appendix Table 21 are calculated and applied for each sub-group of initially symptomatic acute COVID-19 survivors. For symptom-specific costs, proportions reflect long COVID symptom frequencies calculated for each patient sub-group (see long COVID morbidity section above for methodology). GP and specialist attendance proportions applied from the aforementioned literature are multiplied by an OR of 0.55 and separately by an OR of 0.25 to reflect use in vaccinated sub-groups and for low virulence variant infections (e.g., Omicron), respectively (in line with long COVID morbidity estimates).⁶²⁻⁶⁴

Patient subgroup	Treatment item	Source	
	GP visit	20% acute COVID-19 community cases have 1-2 visits, 7% 3- 5 visits, 1% 6 visits. ⁸³ For vaccinated groups, proportions are multiplied by an OR of 0.55. For low virulence variant groups, proportions are multiplied by an OR of 0.25.	
	Specialist visit	18% who see GP (above) are referred to specialist. ⁸⁴ Assume single visit. For vaccinated groups, proportions are multiplied by an OR of 0.55. For low virulence variant groups, proportions are multiplied by an OR of 0.25.	
Community (acute infection) adult cases	ER visit	Assume those with dyspnoea and those with chest pain present to ER once. Standard ER presentation cost for asthma (to represent dyspnoea) and chest pain, are applied.	
	Medication (budesonide, salbutamol)	Assume patients with dyspnoea are prescribed either salbutamol or budesonide (50/50 split) (single prescription with 5 repeats, equating to approximately 6 months use).	
	Medication (paracetamol)	Assume patients with muscle/joint pain and headache purchase 1 packet of paracetamol.	
	Diagnostics	Iron studies for those with fatigue to rule out anaemia, per RACGP guidelines. ⁸² Routine testing of FBC, electrolytes and TFTs also included for this group.	
	GP visit	During first 6 months, 44% 1-2 visits, 12% 3-5 visits, 5% 6 visits. ⁸³ Proportions halved in the second 6 months, to reflect longer duration of symptoms compared to non-hospitalised patients. For vaccinated groups, proportions are multiplied by an OR of 0.55.	
	Specialist visit	18% who see GP are referred to specialist. ⁸⁴ Assume single visit.	
Hospitalised (acute infection) adult cases	ER visit	Assume those with dyspnoea and those with chest pain present to ER once. Standard ER presentation cost for asthma (to represent dyspnoea) and chest pain, are applied.	
	Diagnostics	Iron studies for those with fatigue to rule out anaemia, per RACGP guidelines. Also include routine FBC, electrolytes and TFT testing.	
	Medication (budesonide, salbutamol)	Assume patients with dyspnoea are prescribed either salbutamol or budesonide (50/50 split) (single prescription with 5 repeats, equating to approximately 6 months use). Proportions halved in the second 6 months, to reflect longer duration of symptoms compared to non-hospitalised patients.	

Appendix Table 21: Resource use assumptions for COVID-19 survivors by SARS-CoV-2 category

Medication (paracetamol)	Assume patients with muscle/joint pain and headache
	purchase 1 packet of paracetamol.

GP: general practitioner; ER: emergency room; FBC: full blood count; TFT: thyroid function tests.

Appendix Table 22: Unit costs for long COVID healthcare resource use by COVID-19 survivors

Resource and cost (2022 AUD)	Source	Detail
<u>ER visits</u>		
ER visit for chest pain \$998.97 (plus \$199.79 for 20% pandemic loading) ER visit for dyspnoea \$907.68 (plus \$181.54 for 20% pandemic loading)	Data from NHCDC Report Round 2014 (financial year 2019-20) ⁷⁹	Average cost per ER presentation, using AECC codes for chest pain and asthma (complexity level B for each). Adjusted to 2022 value.
Medication		
Budesonide (dyspnoea) \$40.13	PBS item 2065Q (500μg/2mL inhalation solution, 30 x 2mL ampoules) ⁸⁶	PBS fee for budesonide with 5 repeats
Salbutamol (dyspnoea)	PBS item 8288F (100µg/actuation	PBS fee for salbutamol with 5
\$26.30	inhalation, 200 actuations) ⁸⁷	repeats
Paracetamol (headache/muscle/joint pain) \$6.80 GP consultation	PBS item 10582Y (500mg tablets, 100 units) ⁷⁷ MBS item 23. Level B General	PBS fee for paracetamol with 1 repeat MBS fee for standard attendance
\$39.10 Specialist consultation	MBS item 104 Initial referred	by general practitioners. MBS fee for standard initial
\$76.80	consultation. ⁸⁸	attendance by specialist practitioner.
Pathology testing		
Iron studies \$27.70	MBS item 66596 ⁸⁹	MBS fees for pathology testing items.
TFT	MBS item 66719 ⁹⁰	
\$29.60		
FBE (including FBC) \$14.45	MBS item 65070 ⁹¹	
Electrolytes \$13.35	MBS item 66509 ⁹²	

ER: emergency room; NHCDC: national hospital cost data collection; AECC: Australian emergency care classification; PBS: pharmaceutical benefits scheme; GP: general practitioner; MBS: Medicare benefits schedule; TFT: thyroid function tests; FBE: full blood examination; FBC: full blood count

All costs in Australian dollars

The total cost for each patient sub-category is presented in Appendix Table 23. Each overall cost is applied to the relevant sub-group of all previously symptomatic acute COVID-19 survivors.

Population group		Unvaccinated (95% UI)	Vaccinated (95% UI)		
High virulence variant symptomatic					
Adults	Non-hospitalised	\$95.29 (39.26-151.32)	\$52.98 (21.83-84.14)		
	Hospitalised	\$269.76 (111.14-428.37)	\$148.37 (61.13-235.60)		
Low virulence variant symptomatic					
Adults	Non-hospitalised	\$24.08 (9.92-38.24)	\$13.25 (5.46-21.03)		
	Hospitalised	\$269.76 (111.14-428.37)	\$148.37 (61.13-235.60)		

Appendix Table 23: Cost per patient category

UI applied using +/-30%, in line with uncertainty applied for long COVID morbidity estimates. Costs apply to adults (\geq 18 years). All costs in Australian dollars.

5.4 Intervention costs

Appendix Table 24: Vaccine and respirator costs

	Item	Price (2022 AUD)	SD	Source
Vaccination costs	Current mRNA vaccine (per dose)	\$35	10%	Reported in ⁹³
	Omicron-specific vaccine (per dose)*	\$44	10%	Estimated 1.25 times the cost of current generation mRNA vaccine
	Multivalent vaccine (per dose)*	\$52.50	10%	Estimated 1.5 times the cost of current generation mRNA vaccine
	Vaccine transport (per dose)	\$1	10%	Estimate
	Personnel, consumables, waste management (per dose)	\$30	10%	Relevant MBS items for GP administration of vaccines and rebate for pharmacy administration ⁹⁴⁻⁹⁷
	Overheads (per dose)	\$1	10%	Estimate
	Promotion and advertising (per month)	\$615,000	20%	Australian Government Department of Finance report on COVID-19 vaccination

	Respirator costs (per person, per round, i.e., 10 masks)	\$14.70	10%	campaign advertising spending 2020-2021 financial year, scaled to Victorian population and one month, updated to 2022 cost and rounded to nearest \$5,000 ⁹⁸ Commercial price for N95 masks in Australia (quoted from supplier, for bulk order)
Respirator costs	Distribution cost (per person, per round)	\$2.73	10%	Assumed 20% of the cost of vaccine administration cost and 2.2 persons aged ≥10 years in each household collecting respirators
	Overheads (per person, per round)	\$0.09	10%	Assumed 20% of that for vaccination program and 2.2 persons aged ≥10 years in each household collecting respirators
	Promotion and advertising (per month)	\$460,000	20%	Estimated from Australian Government Department of Finance report on general COVID-19 health campaign advertising spending 2020-2021 financial year, scaled to Victorian population and one month, updated to 2022 cost and rounded to nearest \$5,000 ⁹⁸
	Mask storage over 18 months (full stockpile)	\$295,000	20%	6,400 respirators per pallet, commercial price for storage \$4.50 per pallet per week (quoted from supplier), 10 respirators per person per round, approximately 586,250

		≥10-year-olds in Victoria.
		Rounded to nearest \$5,000

*Uncertainty on Omicron-specific and multivalent vaccine dose costs 100% correlated All costs in Australian dollars

Regarding fixed costs for vaccines, three months of promotion and advertising is conducted per vaccination rollout event (i.e., with each subsequent dose that becomes available). For respirators, promotion and advertising continues for the duration spent in stages 3 and above, and the storage cost of the stockpile applies once (on 1 April 2022) whenever the mask policy option is active in the model.

5.5 GDP costs of stages of PHSMs

We updated previously published estimates of GDP loss due to government-imposed pandemic control interventions⁹⁹ to estimate the current economic impact of time spent in various stages of PHSMs. Due to societal changes since the beginning of the pandemic (such as adaptations to facilitate remote working) we assumed no GDP impacts in stages 1 and 2. GDP loss in stages 3 – 5 in 2022 and 2023 are difficult to estimate but given societal change we assumed wide uncertainty of 10% to 50% (uniform distribution) of the GDP losses per week estimated in 2020. GDP losses per stage were thus estimated by the following (Appendix Table 25):

Stage	GDP loss per week in stage (AUD billions, Victoria only)
1	\$0
2	\$0
3	10% to 50% (uniform distribution) of \$0.725
4	10% to 50% (uniform distribution) of \$1.275
5	10% to 50% (uniform distribution) of \$2.61

Appendix Table 25: GDP loss by stage of PHSMs (per week)

5.6 Unrelated disease costs

Consistent with recommended practice in cost effectiveness analyses,¹⁰⁰⁻¹⁰³ we included 'unrelated disease costs' in the economic evaluation. This means that in addition to including the health expenditure on SARS-CoV-2 cases as above, future changes in health system expenditure are also included. This means that if someone dies due to SARS-CoV-2 infection, their reduced health expenditure in the future is included (leading to a potentially net negative expenditure depending on the balance of costs, age and discount rate).

We estimated these future health expenditure savings for each COVID-19 death in the 18-month intervention duration, using an approach similar to that above for future HALY losses (Appendix Table 17). Specifically, we used lifetables with sex and age-specific all-cause mortality rates (double that of the general population due to people dying of COVID-19 having more co-morbidities and frailty) to estimate remaining life years. For each expected remaining life-year, 1.5 times (due to greater comorbidities) the sex and age-specific expected annual health expenditure according to AIHW estimates¹⁰⁴ was allocated.

We assumed variable health expenditure was 90%, allowing 10% for fixed costs in running services. AIHW estimates capture 62.7% of total health expenditure, therefore we multiplied all age by sex empirical estimates by a factor of 90/62.7 to generate the estimated predicted Australian variable health expenditure per capita, by age and sex. Next, we adjusted these expenditures for inflation to 2022 Australian dollars using Australian consumer price index adjustment factors. Finally, we also generated US dollar values using OECD purchasing power parity (<u>https://data.oecd.org/price/inflationcpi.htm</u>; 2021 PPP used as 2022 not available at the time of writing).

Appendix Table 26 shows future averted health expenditure per COVID-19 death (discount rate 3%). Males and females are not distinguished separately in the ABM. Therefore, also shown in Appendix Table 26 are averages by sex, which are used in the modelling. Noting the SD about the sex-specific estimates, we set the SD as 15% of the age-specific estimates (normal distribution).

Appendix Table 27 shows future averted health expenditure at the discount rate of 3.5% as recommended by the UK Treasury⁷¹ (with the same % SD for uncertainty as in Appendix Table 26).

Appendix Table 26: Future averted health expenditure for each COVID-19 death (3% discount rate), by sex and age

	Females			Males		Combined (average of males and females)		
Age group	Expected value, AUD, CPI adjusted to 2022	Expected value, USD, OECD PPP adjusted	SD in Monte Carlo uncertainty analyses as % of expected	Expected value, AUD, CPI adjusted to 2022	Expected value, USD, OECD PPP adjusted	SD in Monte Carlo uncertainty analyses as % of expected	Expected value, AUD, CPI adjusted to 2022	Expected value, USD, OECD PPP adjusted
0-9 yrs	\$79,825	\$54,526	15.90%	\$97,190	\$66,387	12.40%	\$88,508	\$60,457

10-19 yrs	\$90,913	\$62,099	15.70%	\$77,596	\$53,003	12.10%	\$84,255	\$57,551
20-29 yrs	\$158,112	\$108,000	15.70%	\$79,192	\$54,093	12.30%	\$118,652	\$81,047
30-39 yrs	\$215,990	\$147,534	15.00%	\$99,970	\$68,285	11.70%	\$157,980	\$107,910
40-49 yrs	\$175,489	\$119,869	14.00%	\$128,337	\$87,662	11.10%	\$151,913	\$103,766
50-59 yrs	\$180,501	\$123,293	13.60%	\$160,764	\$109,811	11.00%	\$170,633	\$116,552
60-69 yrs	\$193,058	\$131,870	13.90%	\$191,507	\$130,811	11.20%	\$192,283	\$131,341
70-79 yrs	\$188,429	\$128,708	14.40%	\$188,763	\$128,936	11.50%	\$188,596	\$128,822
80-89 yrs	\$123,066	\$84,061	14.70%	\$130,017	\$88,810	11.70%	\$126,542	\$86,436
90-99 vrs	\$56,881	\$38,853	14.30%	\$67,573	\$46,157	11.60%	\$62,227	\$42,505

AUD: Australian dollars, USD: US dollars, CPI: consumer price index, OECD: Organisation for Economic Co-operation and Development, PPP: purchasing power parity, SD: standard deviation 100% correlation on uncertainty between age groups

Appendix Table 27: Future averted health expenditure for each COVID-19 death (3.5% discount rate), by sex and age

	Females	Males	Combined (average males & females)
	Expected	Expected	Expected
Aae	value, value,		value,
aroun	AUD, CPI	AUD, CPI	AUD, CPI
group	adjusted	adjusted	adjusted to
	to 2022	to 2022	2022
0-9 yrs	\$69,103	\$84 <i>,</i> 459	\$76,781
10-19 yrs	\$79,331	\$67,810	\$73,570
20-29 yrs	\$139,561	\$70,328	\$104,944
30-39 yrs	\$192,419	\$89,641	\$141,030
40-49 yrs	\$158,200	\$116,688	\$137,444
50-59 yrs	\$165,886	\$149,004	\$157,445
60-69 yrs	\$181,354	\$181,151	\$181,252
70-79 yrs	\$180,690	\$181,910	\$181,300

80-89 yrs	\$120,000	\$127,094	\$123,547
90-99 yrs	\$56,044	\$66,613	\$61,328
100-109			
yrs	\$42,507	\$52,934	\$47,720

6 **REFERENCES**

1. Zhang M, Xiao J, Deng A, et al. Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B.1.617.2 - Guangdong Province, China, May-June 2021. *China CDC Wkly* 2021; **3**(27): 584-6.

2. Trauer JM, Lydeamore MJ, Dalton GW, et al. Understanding how Victoria, Australia gained control of its second COVID-19 wave. *Nature Communications* 2021; **12**(1): 6266.

3. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and metaanalysis. *Official Journal of the Association of Medical Microbiology and Infectious Disease Canada* 2020; **5**(4): 223-34.

4. Zhang J, Litvinova M, Liang Y, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* 2020; **368**(6498): 1481-6.

5. Szanyi J, Wilson T, Scott N, Blakely T. A log-odds system for waning and boosting of COVID-19 vaccine effectiveness. *Vaccine* 2022; **40**(28): 3821-4.

6. The Australian COVID-19 Serosurveillance Network. Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors, February–March 2022, 2022.

7. Talic S, Shah S, Wild H, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. *BMJ* 2021; **375**: e068302.

8. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020; **395**(10242): 1973-87.

9. Chu D, Khamis A, Akl E, Neumann I, Solo K, Schunemann H. Revisiting the evidence for physical distancing, face masks, and eye protection - Authors' reply. *Lancet* 2021; **398**(10301): 663-4.

10. Andrejko KL, Pry JM, Myers JF, et al. Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection - California, February-December 2021. *MMWR* - *Morbidity & Mortality Weekly Report* 2022; **71**(6): 212-6.

11. Ying B, Scheaffer SM, Whitener B, et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. *Cell* 2022; **185**(9): 1572-87.e11.

12. Pfizer Inc. and BioNTech SE. Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron [Press release]. 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19 (accessed July 14 2022).

13. Joyce MG, King HAD, Elakhal-Naouar I, et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. *Science Translational Medicine* 2022; **14**(632): eabi5735.

14. Vaxart Inc. New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses [Press release]. 2021. <u>https://investors.vaxart.com/news-</u> <u>releases/news-release-details/new-data-vaxart-oral-covid-19-vaccine-phase-i-study-suggests</u> (accessed July 14 2022). 15. Langel SN, Johnson S, Martinez CI, et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. *Sci Transl Med* 2022: eabn6868.

16. Moderna. Moderna's Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrates significantly higher neutralizing antibody response against Omicron subvariants BA.4/5 compared to currently authorized booster [Press release]. 2022.

https://investors.modernatx.com/news/news-details/2022/Modernas-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Significantly-Higher-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA.45-Compared-To-Currently-Authorized-Booster/default.aspx (accessed July 14 2022).

17. Shearer F, Bennett C, Vally H, McCaw J, Golding N. New COVID variants may be more transmissible but that doesn't mean the R0 – or basic reproduction number – has increased. 2022. https://theconversation.com/new-covid-variants-may-be-more-transmissible-but-that-doesnt-mean-the-r0-or-basic-reproduction-number-has-increased-186826 (accessed 31 July 2022).

18. Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. *New England Journal of Medicine* 2022; **386**(7): e14.

19. Markov PV, Katzourakis A, Stilianakis NI. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. *Nature Reviews Microbiology* 2022; **20**(5): 251-2.

20. COVID-19 Forecasting Team. Variation in the COVID-19 infection—fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. *The Lancet* 2022.

21. Knock ES, Whittles LK, Lees JA, et al. Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England. *Sci Transl Med* 2021; **13**(602).

22. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proceedings of the National Academy of Sciences* 2021; **118**(34): e2109229118.

23. Tobin RJ, Wood JG, Jayasundara D, et al. Hospital length of stay in a mixed Omicron and Delta epidemic in New South Wales, Australia. *medRxiv* 2022: 2022.03.16.22271361.

24. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B. 1.1. 529) variant. *New England Journal of Medicine* 2022.

25. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. *New England Journal of Medicine* 2022.

26. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *The Lancet* 2022.

27. UK Health Security Agency. COVID-19 vaccine surveillance report - week 5, 2022.

28. UK Health Security Agency. COVID-19 vaccine surveillance report - week 15, 2022.

29. UK Health Security Agency. COVID-19 vaccine surveillance report - week 13, 2022.

30. Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. *New England Journal of Medicine* 2022.

31. Magen O, Waxman JG, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *New England Journal of Medicine* 2022; **386**(17): 1603-14.

32. Yu J, Collier A-rY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. *New England Journal of Medicine* 2022.

33. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *New England Journal of Medicine* 2022.

34. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. *N Engl J Med* 2022.

35. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *The Lancet Infectious Diseases* 2022; **22**(6): 781-90.

36. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet* 2021; **397**(10280): 1204-12.

37. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet* 2021; **397**(10283): 1459-69.

38. Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study. *Clin Infect Dis* 2021.

39. Rennert L, McMahan C. Risk of SARS-CoV-2 reinfection in a university student population. *Clinical Infectious Diseases* 2021; **16**: 16.

40. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. *Clinical Infectious Diseases* 2021; **73**(10): 1882-6.

41. Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) - Kentucky, USA, 2020. *International Journal of Infectious Diseases* 2022; **114**: 21-8.

42. Milne G, Hames T, Scotton C, et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? *The Lancet Respiratory Medicine* 2021; **9**(12): 1450-66.

43. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid COVID-19 immunity. *medRxiv* 2021: 2021.12.04.21267114.

44. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. *New England Journal of Medicine* 2022.

45. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. *N Engl J Med* 2022; **386**(13): 1207-20.

46. Gazit S, Shlezinger R, Perez G, et al. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study. *Annals of Internal Medicine* 2022; **15**: 15.

47. Hammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. *New England Journal of Medicine* 2022; **16**: 16.

48. Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. *medRxiv* 2022: 2022.01.28.22270044.

49. Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. *New England Journal of Medicine* 2022; **386**(8): 744-56.

50. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2020; **396**(10258): 1204-22.

51. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. *The Lancet* 2022; **399**(10335): 1618-24.

52. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado ML, Florencio LL. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. *Int J Environ Res Public Health* 2021; **18**(5).

53. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *The Lancet Infectious Diseases* 2022; **22**(4): e102-e7.

54. World Health Organization. Emergency use ICD codes for COVID-19 disease outbreak. 2022. https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-forcovid-19-disease-outbreak (accessed 06/04/2022 2022).

55. Smith MP. Estimating total morbidity burden of COVID-19: relative importance of death and disability. *J Clin Epidemiol* 2022; **142**: 54-9.

56. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine* 2021; **38**: 101019.

57. Nguyen NN, Hoang VT, Dao TL, Dudouet P, Eldin C, Gautret P. Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review. *Eur J Clin Microbiol Infect Dis* 2022; **41**(4): 515-45.

58. Vedel Sørensen AI, Spiliopoulos L, Bager P, et al. Post-acute symptoms, new onset diagnoses and health problems 6 to 12 months after SARS-CoV-2 infection: a nationwide questionnaire study in the adult Danish population. *medRxiv* 2022: 2022.02.27.22271328.

59. Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. *Eur J Epidemiol* 2022; **37**(5): 539-48.

60. Magnúsdóttir I, Lovik A, Unnarsdóttir AB, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. *The Lancet Public Health* 2022; **7**(5): e406-e16.

61. Behnood SA, Shafran R, Bennett SD, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. *J Infect* 2022; **84**(2): 158-70.

62. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *The Lancet Infectious Diseases* 2022; **22**(1): 43-55.

63. Office for National Statistics. Self-reported long COVID after two doses of a coronavirus (COVID-19) vaccine in the UK, 2022.

64. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. *Lancet* 2022; **399**(10343): 2263-4.

65. van Baal PHM, Hoeymans N, Hoogenveen RT, de Wit AG, Westert GP. Disability weights for comorbidity and their influence on Health-adjusted Life Expectancy. *Population Health Metrics* 2006; **4**(1): 1.

66. Wulf Hanson S, Abbafati C, Aerts JG, et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. *medRxiv* 2022.

67. Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. *Lancet Child Adolesc Health* 2021; **5**(10): 708-18.

68. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study. *European Journal of Pediatrics* 2022.

69. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ* 2021; **372**: n693.

70. Ministry of Health. Health Loss in New Zealand: A report from the New Zealand Burden of Diseases, Injuries and Risk Factors Study, 2006–2016. Wellington, New Zealand, 2013.

71. HM Treasury. The Green Book: Central Government Guidance on Appraisal and Evaluation. London, United Kingdom, 2022.

72. Victorian Government. Victorian COVID-19 data. 2022.

https://www.coronavirus.vic.gov.au/victorian-coronavirus-covid-19-data (accessed July 15 2022).

73. Australian Government Department of Health and Aged Care. Coronavirus (COVID-19) common operating picture – 5 April 2022, 2022.

74. Australian Government Department of Health and Aged Care. Medicare Benefits Schedule - Item 69479. <u>http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=69479</u> (accessed July 15 2022).

75. Australian Competition and Consumer Commission. Update on action on rapid antigen test pricing. 2022. <u>https://www.accc.gov.au/media-release/update-on-action-on-rapid-antigen-test-pricing</u> (accessed July 15 2022).

76. Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis. *Am J Emerg Med* 2022; **51**: 267-79.

77. Pharmaceutical Benefits Scheme. Paracetamol. <u>https://www.pbs.gov.au/medicine/item/10582y</u> (accessed 2022 Jun 28 2022).

78. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 23.

<u>http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=23</u> (accessed 2022 Jun 28 2022).
 79. Independent Hospital Pricing Authority. National Hospital Cost Data Collection (NHCDC) Report: Public Sector, Round 24 Appendix (financial year 2019-20). Sydney (NSW), 2022.

80. Higgins AM, Pettilä V, Harris AH, et al. The critical care costs of the influenza A/H1N1 2009 pandemic in Australia and New Zealand. *Anaesth Intensive Care* 2011; **39**(3): 384-91.

81. National COVID Clinical Evidence Taskforce. Care of People with Post-COVID-19. 2022. https://covid19evidence.net.au/wp-content/uploads/FLOWCHART-11-CARE-OF-PEOPLE-WITH-POST-COVID19-V4.0.pdf?=220408-71456 (accessed 26 Apr 2022.

82. Royal Australian College of General Practitioners. Caring for Patients with Post-COVID-19 Conditions. East Melbourne, Victoria, Australia, 2021.

83. Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. *PLoS One* 2021; **16**(7): e0254523.

84. Heightman M, Prashar J, Hillman TE, et al. Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. *BMJ Open Respir Res* 2021; **8**(1).

85. Magnusson K, Skyrud KD, Suren P, et al. Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study. *BMJ* 2022; **376**: e066809.

86. Pharmaceutical Benefits Scheme. Budesonide. <u>https://www.pbs.gov.au/medicine/item/2065q</u> (accessed 2022 Jun 28 2022).

87. Pharmaceutical Benefits Scheme. Salbutamol. <u>https://www.pbs.gov.au/medicine/item/8288F</u> (accessed 2022 Jun 28 2022).

88. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 104.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=104&qt=item (accessed 2022 Jun 28 2022).

89. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 66596.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=66596&qt=item (accessed 2022 Jun 28 2022).

90. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 66719.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=66719&qt=item (accessed 2022 Jun 28 2022).

91. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 65070.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=65070&qt=item (accessed 2022 Jun 28 2022).

92. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 66509.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=66509&qt=item (accessed 2022 Jun 28 2022).

93. Light DW, Lexchin J. The costs of coronavirus vaccines and their pricing. *Journal of the Royal Society of Medicine* 2021; **114**(11): 502-4.

94. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 93644.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=93644 (accessed 2022 Jul 15 2022).

95. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 93666.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=93666&qt=item&criteria=93666 (accessed 2022 Jul 15 2022).

96. Medicare Benefits Schedule. Medicare Benefits Schedule - Item 93645.

http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=93645&qt=item&criteria=93645 (accessed 2022 Jul 15 2022).

97. The Pharmacy Guild of Australia. COVID-19 Vaccination. 2022.

https://www.guild.org.au/resources/business-operations/covid-19/vaccination (accessed July 15 2022).

98. Australian Government Department of Finance. Campaign Advertising by Australian Government Departments and Agencies Report 2020–21, 2021.

99. Blakely T, Thompson J, Bablani L, et al. Association of Simulated COVID-19 Policy Responses for Social Restrictions and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria, Australia. *JAMA Health Forum* 2021; **2**(7): e211749-e.

100. van Baal P, Meltzer D, Brouwer W. Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis. *Health Econ* 2016; **25**(2): 237-48.

101. van Baal P, Morton A, Meltzer D, Brouwer W. Future unrelated medical costs need to be considered in cost effectiveness analysis. *The European Journal of Health Economics* 2019; **20**(1): 1-5.
102. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health

and Medicine. Jama 2016; 316(10): 1093-103.
103. Versteegh M, Knies S, Brouwer W. From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. *Pharmacoeconomics* 2016; 34(11): 1071-4.

104. Australian Institute of Health and Welfare. Disease expenditure in Australia 2018-19. Canberra: AIHW, 2021.